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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 The goal of this introductory chapter is to provide background information on 
concepts relevant to the original scientific data presented in this manuscript. As such, 
the following text will first describe the scope, current treatments, and immunologic 
mechanisms of airway inflammation studied in this manuscript, including allergic airway 
inflammation, bacterial infection and asthma, and respiratory syncytial virus (RSV) 
infection. Subsequent sections will provide an overview of the signaling pathways, 
biology, and role in disease of immune modulators that are the therapeutic targets for 
inflammatory airway disease in this work. The final section will highlight what this work 
contributes to our knowledge of the regulation of immune responses during airway 
inflammation. 
 
Scope, current treatments, and immunologic mechanisms of airway inflammation 
Allergic airway inflammation 
 In the last several decades, the prevalence of allergic rhinitis, asthma, and atopic 
eczema increased markedly in developed countries.1,2 Allergic disease has become one 
of the most common causes of chronic illness and affects 300 million people worldwide, 
including 40-50 million Americans.1 Epidemiologic investigations reveal that roughly a 
quarter of the U.S. population suffers from allergic diseases.3 Similar trends have begun 
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to emerge in developing countries that have witnessed progressive westernization.4,5 In 
particular, the Center for Disease Control and Prevention reported that among persons 
of all ages, the prevalence of asthma increased by 12.3% from 2001 to 2009, with 25 
million Americans being affected with this disease.6 Direct costs from asthma are 
approximately $50.1 billion and the indirect costs resulting from lost earnings due to 
illness or death are roughly $5.9 billion.7 In children ages 5 to 17, asthma is one of the 
leading causes of school absences and accounts for an annual loss of 10.5 million 
school days.7  
 The most common form of asthma is allergic asthma which is characterized by 
increased eosinophilic infiltration, IgE production, and the production of CD4+ Th2 
cytokines, such as IL-4, IL-5, and IL-13. Initiation of the allergic immune response starts 
with immune recognition of common environmental antigens by specialized antigen-
presenting cells (APCs) such as DCs, macrophages, and B lymphocytes among several 
other cells types (Figure 1.1).8,9 Antigens processed by APCs through the endocytic 
pathway are presented as 8-10 amino acid epitopes in MHC class II molecules to CD4+ 
T lymphocytes. CD4+ T lymphocytes are generally divided into subsets including Th1, 
Th2, Th17, and induced-T regulatory cells (iTregs). CD4+ T cell subsets are 
characterized by the cytokine array produced by the cell (Figure 1.2). Both Th1 and Th2 
lymphocytes cooperate in generating the allergic phenotype.10 Th1 cells are important in 
the immune response to intracellular pathogens such as viruses and mycobacteria and 
produce IFN-γ, lymphotoxin, and IL-2.11 Th2 cells are differentiated in the presence of 
IL-4 produced by cells including basophils and mast cells, and Th2 lymphocytes 
cooperate in generating the allergic phenotype. Once differentiated, Th2 cells produce 
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Figure 1.1. The immunology of asthma. Adaptive Th2 cells are stimulated by DCs to 
produce IL-5, IL-13, and IL-4, resulting in eosinophilic airway inflammation and AHR. 
ILC2 produce IL-5 and IL-13 which leads to eosinophilia and AHR. Adapted from 
Lambrecht BN and Hammad H, Nat Immunol, 2015.12  
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Figure 1.2. Th differentiation from naïve CD4+ T cells. Naïve CD4+ T cells 
differentiate into Th1 cells in the presence of IL-12, Th2 cells in the presence of IL-4, 
Th17 cells in the presence of TGF-β and IL-6, and Tregs in the presence of TGF-β. 
Adapted from Leung S et al. Cell Mol Immunol, 2010.13 
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IL-4, an important factor for B lymphocytes to switch antibody production to the IgE 
isotype.11 Th2 cells additionally make a variety of other pro-allergic inflammatory 
cytokines such as IL-5 and IL-13. IL-5 is the most important cytokine in eosinophil 
growth, differentiation, and survival, and eosinophilic inflammation is one of the 
hallmarks of the allergic inflammatory response in the airway.14 IL-13 is a central 
mediator in airway hyperreactivity (AHR) and mucus expression.11,14 The allergic 
response to an aerosolized antigen is characterized by antigen-specific IgE production 
by B lymphocytes, whereupon IgE can bind to IgE receptors on tissue mast cells and 
peripheral blood basophils. When these antigen-specific IgE molecules bound to mast 
cells and basophils are cross-linked by the specific antigen on antigenic re-exposure, 
the mast cells and basophils undergo a degranulation process. With degranulation, 
preformed mediators within the mast cell and basophil such as histamine and tryptase 
are released.14  
 Group 2 innate lymphoid cells (ILC2) are early, important mediators of airway 
responsiveness, eosinophilia, and mucus production.15–19 ILC2 are temporally and 
functionally distinct from Th2 cells. Lung ILC2 are lineage negative (Lin-) in that they do 
not express CD3ε, CD19, CD11b, Gr-1, NK1.1, or Ter119.15 There is some controversy 
about the surface expression of a variety of proteins including SCA-1, c-kit, ICOS, 
CD45, and ST2, largely because different groups have used different combinations of 
these molecules to phenotype ILC2.15,16,19,20 However, there seems to be complete 
consensus that ILC2 have surface expression of CD25 (IL-2Rα) and CD127 (IL-
7Rα).15,16,19,20 Lung resident ILC2 express high levels of IL-5 and IL-13, but minimal IL-
4.20 This is in contrast to mature effector Th2 cells that express all three cytokines. 
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Comparatively, early reports suggest that ILC2 are significantly more potent than Th2 
cells, elaborating greater than 10 times the amount of Th2 cytokines on a per cell 
basis.20 ILC2 are critical for generating type 2 inflammation because they recruit 
dendritic cells into the draining lymph node to promote Th2 cell differentiation locally in 
the airway wall.21 ILC2 also help establish the adaptive type 2 response by expressing 
MHC and costimulatory signals that trigger type 2 cytokine production.22 CD4+ Th2 cell 
and basophils concomitantly enhance ILC2 responses by promoting ILC2 proliferation 
and cytokine production via IL-2 and IL-4 production respectively.22,23 Unlike T and B 
cells, ILC2 do not have specific antigen receptors. Rather, ILC2 act primarily as early 
innate effector cells that respond directly to cytokine stimulation.24–26 Specifically, the 
epithelial-associated cytokines IL-25, IL-33, and TSLP induce ILC2 proliferation and 
activation.15,24–26 
IL-33 is constitutively expressed in the nucleus of epithelial and endothelial cells, 
and is released upon cell injury as an alarmin.27 As a result of being expressed by cells 
that interface with the environment, IL-33 functions as an early initiator of inflammation. 
In addition, IL-33 expression is stimulated in inflamed tissues and can further amplify 
inflammatory responses. It is a member of the IL-1 family and extracellular IL-33 binds 
to its receptors, ST2 and IL-1 Receptor Accessory Protein (IL1RAP), inducing NF-κB 
and MAPK activation. IL-33 activates cells that produce type 2 cytokines including ILC2, 
Th2 cells, and basophils to secrete IL-13. IL-33 additionally potentiates type 2 immune 
responses by polarizes naïve CD4+ T cells to differentiate into type 2 cytokine-producing 
effector Th2 cells.28 As a central mediator of both innate and adaptive immunity-
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regulated lung inflammation, IL-33 has been identified as an important therapeutic 
target in inhibiting airway disease.29 
In many patients, allergic asthma can be controlled by a combination of an 
inhaled corticosteroid (which acts to suppress the inflammation) and a short- or long-
acting β2-adrenergic agonist (which acts to relax the constricting bronchial smooth 
muscle). However, in 5–10% of patients, allergic asthma is refractory to corticosteroid 
treatment and often leads to hospital admissions caused by respiratory viral and/ or 
bacterial infections. Treatment with an antibody to the α-chain of the receptor for IL-4 
(dupilumab; Regeneron Pharmaceuticals), which blocks downstream signaling via the 
receptors for IL-4 and IL-13, improves lung function and reduces the frequency of 
exacerbation in people with moderate to severe asthma with high levels of eosinophils 
in the blood.30 In a phase 2 trial, blocking IL-13 with lebrikizumab (Genentech) also 
improved lung-function parameters, particularly in patients with the Th2hi endotype of 
asthma.31 Eliminating eosinophils through the use of an antibody to IL-5 (mepolizumab; 
GlaxoSmithKline) led to a reduction in exacerbation frequency in a subset of patients 
with high levels of circulating blood eosinophils and frequent exacerbations, even in 
those receiving inhaled steroids.32 As exacerbations often require systemic steroids that 
have serious side effects, blocking IL-5 can therefore reduce the use of oral steroids. In 
people with asthma in whom IL-5 was blocked, there was also a significant reduction in 
the deposition of extracellular matrix components tenascin, lumican and procollagen III, 
possibly leading to less airway remodeling.33 A new drug that targets eosinophils and is 
currently under phase 3 clinical development is an antibody to the receptor for IL-5 
(benralizumab; AstraZeneca/MedImmune), which effects depletion of eosinophils for 
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months after a single injection.34 The drug omalizumab (Xolair; Genentech/Novartis) is a 
humanized monoclonal antibody that binds to the constant domain of IgE, inhibiting its 
interaction with the high-affinity receptor FcεRI, and has proven efficacy in a subset of 
patients. However, omalizumab must be administered for a few weeks before showing 
clinical effects in patients, suggesting that omalizumab does not work by inhibiting the 
early degranulation of mast cells or basophils. Prolonged treatment with omalizumab 
also results in a reduction in Th2 cytokine production in lung tissues, suggesting that it 
affects the generation of effector Th2 responses.35 
IL-17A levels and IL-17A-producing cells are increased in the sputum of 
asthmatic patients with bronchial reactivity.36,37 IL-17A expression was also significantly 
greater in bronchial biopsy specimens in the airways of subjects with moderate-to-
severe asthma compared to subjects with mild asthma or controls.38 There are six 
family members of IL-17, designated IL-17A-F. IL-17F is produced by the same cells 
that produce IL-17A and also signals through the IL-17RA/ IL-17RC heterodimeric 
complex; therefore, IL-17F has very similar functions as IL-17A.39 The first described IL-
17 receptor was designated IL-17R and primarily binds IL-17A.40 Surprisingly, a clinical 
trial with a antibody that neutralizes the receptor for IL-17 (brodalumab; 
Amgen/AstraZeneca), blocking the activity of IL-17A, IL-17F and IL-25, has shown only 
minimal effects on outcome measures of asthma in mild to moderate disease.41 It is 
possible that subgroups of patients, particularly those with large numbers of sputum 
neutrophils or with a high degree of lung function reversibility, would respond more 
favorably.42 
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While allergic diseases including asthma have risen considerably in prevalence 
in the last 50 years, a concomitant rise in autoimmune disease suggests a defect in 
immunoregulation, rather than a reduction in Th1 immunity, in the growing prevalence of 
both diseases. Moreover, people without allergic diseases have antigen-specific 
immune tolerance to common aeroallergens. Some studies support the possibility that 
Tregs suppress allergic diseases and contribute to allergen-specific immune 
tolerance.43,44 Tregs are a subtype of CD4+ T cells that are critical for the maintenance 
of self-tolerance and tolerance to foreign antigens by inhibiting effector T cell 
responses.45 Tregs constitute 5-10% of all CD4+ T cells. Natural Tregs (nTregs) 
differentiate in the thymus before their exit into the peripheral circulation. Inducible 
Tregs (iTregs) are generated following exposure to cognate antigen in the context of 
transforming growth factor (TGF)-β and interleukin (IL)-2. The establishment and 
maintenance of tolerance induced by repeated airway exposures to low-dose ovalbumin 
(OVA) were dependent on Treg cells that express both cell surface and soluble TGF-
β.44 Therefore, Treg instability and/ or defective Th2 regulation may be mechanisms by 
which immune tolerance prevents the immune system from responding to innocuous 
environmental antigens.46–52 
 
Bacterial infection and asthma  
Patients with asthma are at increased risk for bacterial infections and bacterial 
pneumonia.53–57 For instance, in a population of Tennessee Medicaid enrollees, asthma 
patients had an almost four-fold increased risk of invasive pneumococcal disease 
compared to nonasthmatics, even when subjects were controlled for medication usage 
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such as inhaled or systemic corticosteroids.55 Furthermore, mouse studies have shown 
that allergic airway inflammation impairs host defense against Streptococcus 
pneumoniae as well as Pseudomonas aeruginosa.58,59  
Klebsiella pneumonia (KP) is a Gram-negative pathogen that causes pneumonia 
and invasive disease in healthy and immunocompromised adults and children.60–63 The 
continued emergence and spread of multidrug-resistant strains of KP highlight the 
importance of developing innovative therapeutic approaches to these infections. Both 
IL-17A and IL-17F were produced as result of KP lung infection. Moreover, mice 
deficient for IL-17R had greater bacteremia and increased mortality to KP infection 
compared to wild type (WT) mice.64 Additional studies have similarly found that IL-17A 
is critical for the clearance of KP from the lung and recovery of the host from infection in 
mouse models.65–67 These findings were likely related to decreased chemotaxis of 
neutrophils into the bronchoalveolar compartments as a consequence of a blunted 
production of granulocytes in the spleen, secondary to inhibited G-CSF expression.66 
The importance of IL-17A for general pulmonary host defense was demonstrated in a 
study showing that anti-IL-17A antibody treatment decreased endotoxin-induced 
neutrophil migration into the lung.68  
γδ17 cells constitute a unique γδ T cell subset that produces IL-17A, IL-17F, and 
IL-22, and are important in innate antibacterial immunity.69 γδ17 cells reside at the 
interface of epithelial-environmental interfaces such as the respiratory tract. Strong early 
γδ17 cell responses are generated against diverse pathogens including KP, 
Mycobacterium tuberculosis, Mycobacterium bovis, Staphylococcus aureus, Listeria 
monocytogenes, and Escherichia coli. γδ T cells responses are critical for immunity 
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against these pathogens.70–75 Following acute infection with KP, IL-17A is rapidly 
expressed within 2 days by γδ T cells and mice deficient in γδ T cells succumb to KP 
infection.70,76,77 IL-17A stimulates neutrophil recruitment, production of antibacterial 
peptides, and maintenance of epithelial barriers.78 In contrast to naïve CD4+ T cells that 
become Th17 cells in the periphery in the context of an immune response, γδ17 cells 
are preprogrammed in the thymus to produce IL-17A.79 In the thymus, lack of T cell 
receptor (TCR) engagement or weak TCR signaling programs developing γδ T cells to 
secrete IL-17A once they enter the periphery. Alternatively, strong TCR engagement 
biases the cell towards an IFN-γ-secreting disposition.79 In vitro, treating γδ T cells with 
IL-1β and IL-23 optimally induces IL-17A production without the need for TCR 
engagement, since γδ17 cells constitutively express the receptors for IL-1 (IL-1R1) and 
IL-23 (IL-23R, Figure 1.3).80 The constitutive expression of IL-1R1 and IL-23R provides 
an efficient mechanism to induce γδ T cell production of IL-17A.81 The development of 
γδ17 cells is controlled by transcription factors RORγT and AhR.69,82 γδ T cells that exit 
the thymus without going through TCR engagement do not repress RORγT expression 
and preferentially develop into γδ17 cells. This differs from Th17 cells, which repress 
RORγT function and require IL-6 and TGF-β to induce the re-expression of RORγT for 
their differentiation.82–84 
 
RSV infection  
 RSV is the most common cause of severe bronchiolitis in infants in the United 
States and throughout the world.85 Several long-term epidemiologic studies reveal that 
severe RSV bronchiolitis in infancy is associated with recurrent wheeze and asthma  
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Figure 1.3. γδ17 cells are innate, potent producers of IL-17. Adaptive Th17 cell 
development and polarization takes 3-5 days. γδ17 reside in peripheral tissues and can 
produce high levels of IL-17 within hours of stimulation. Adapted from Cua D and Tato 
CM, Nat Rev Immunol 2010.81 
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during childhood. In the prospective Tuscon Children’s Respiratory Study of over 1,200 
infants enrolled from 1980-1984, RSV lower respiratory tract illness in early childhood 
was an independent risk factor for the subsequent development of wheezing up to 11 
years of age.86 In a case-control study of Swedish infants born in the winter of 1989-
1990, RSV bronchiolitis which was so severe as to lead to hospitalization resulted in a 
greater than four-fold (39% vs 9%) increased prevalence of asthma at age 18 compared 
to control subjects.87 In a population-based retrospective birth cohort study of term 
healthy infants born between 1995 and 2000 and enrolled in the Tennessee Medicaid 
program, a significant dose-response relationship was demonstrated between the 
severity of infant bronchiolitis and the increased odds of both early childhood asthma 
and asthma-specific morbidity between the ages of 4 and 5½ years of age.88 Among the 
90,341 children examined, 18% had an infant health care visit or hospital admission for 
bronchiolitis, and these infants contributed to 31% of early childhood asthma diagnoses. 
These studies demonstrate the very strong association between severe RSV 
bronchiolitis and the inception of childhood asthma in geographically, economically, and 
temporally diverse populations. 
Conversely, there appears to be synergism between viruses and aeroallergens in 
the risk of hospital admission for asthma exacerbation.89 Allergic disease is the 
strongest identifiable predisposing factor for the development of asthma, and exposure 
to allergens can cause acute asthma symptoms.90 Comparatively, viruses were 
detected in approximately 80% of children with asthma exacerbations,91 and in over half 
of adults with worsening asthma symptoms.92 Although RSV has long been recognized 
as the most common infectious agent that caused wheezing in infants from  
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bronchiolitis,93 more recently this virus has been identified as an important cause of 
asthma exacerbations in both older children and adults as well.94,95 For instance, RSV 
was detected in over 20% of children aged 1-3 years that were hospitalized with 
wheezing, and in approximately 10% of children 3-16 years old that were admitted with 
asthma exacerbations.95 In persons over 65 years of age, RSV was detected in 7% of 
patients admitted to the hospital diagnosed with an asthma exacerbation.94  
 Well-timed, appropriately located, and stringently regulated host immune 
responses are essential for protection from RSV infection and limiting symptoms, while 
poorly regulated inflammation contributes to tissue damage and disease (Figure 1.4). 
The responsiveness of the airway epithelium to the initial stages of RSV infection is 
critical to the subsequent development of adaptive immunity. RSV infects the respiratory 
epithelium, which can recognize pathogen-associated molecular patterns (PAMPs) from 
the virus via pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) and 
intracellular sensors including RIG-I-like receptors (RLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors.96 Ligation of these receptors leads to type 
I and III interferon upregulation. Type I and III interferons subsequently trigger the 
inflammatory response, contribute to the differentiation of adaptive immune cells, and 
promote an antiviral state locally. Inflammatory mediators recruit innate cells, including 
neutrophils and natural killer (NK) cells. NK cells can kill RSV-infected cells via perforin-
granzyme-dependent mechanisms and the type II transmembrane protein cytokine 
FasL via its receptor Fas (CD95). NK cells also produce interferon-γ (IFN-γ) as do Th1 
cells, which potentiates the polarization of recruited T cells to an antiviral, cytolytic type 
1 response which is required for viral clearance.97,98 Following engagement of the T cell  
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Figure 1.4. The host immune response during RSV infection. Anti-viral IFN and IgG 
production lead to disease resolution while poorly regulated immune responses can 
lead to damaging immunopathology. Adapted from Chiu C and Openshaw P, Nat 
Immunol 2015.99 
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antigen receptor and appropriate costimulatory signals, CD8+ T cells acquire cytolytic 
activity and upregulate chemokine receptors that allow them to migrate to inflamed 
sites, where they detect RSV-infected cells by binding to viral peptides presented in the 
context of major histocompatibility complex class I (MHC I). CD4+ T cells recognize viral 
peptides presented by MHC II-bearing cells and differentiate, depending on the 
environmental context and strength of interaction, into helper T cell subsets. Following 
antigen recognition, B cells differentiate with the help of cognate CD4+ Tfh cells to form 
antibody-secreting plasma cells. Class switching to IgG is followed by the secretion of 
large amounts of high-affinity antibody that can directly neutralize RSV, block entry of 
virus into the cell, fix complement, promote phagocytosis, and allow antibody-dependent 
cellular cytotoxicity. However, pathogenic viral mediators can dysregulate host immune 
responses during infection. For example, RSV NS1 and NS2 proteins suppress the 
induction and signaling of type I interferons, DC maturation, and T lymphocyte 
activation; the NS proteins also inhibit apoptosis, prolonging the life of infected cells and 
increasing viral yields.100 In addition, RSV G protein promotes inappropriate 
inflammatory responses via CX3C chemokine mimicry.101 Reduced viral control by 
defective host immunity and over activation of the type 2 host response lead to severe 
RSV infection. The type 2 response mediates airway mucus production, which directly 
contributes to the airway obstruction and respiratory failure.102 
Many studies have examined genetic and environmental factors that modulate 
severity of illness resulting from RSV infection in human infants. Proposed risk factors 
for severe RSV bronchiolitis include age less than one year of age, pre-existing 
bronchopulmonary dysplasia, congenital heart disease, prematurity, age < 3 months at 
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the start of the RSV season, co-habitation with older siblings, maternal smoking, and 
abbreviated breast feeding.103–105 Host genetic factors have also been identified to 
predispose for severe RSV bronchiolitis and include polymorphisms in the genes for IL-
10, CCR5, TGFB1, IL-13, IL-4, and IL-4 receptor.106 Polymorphisms in the toll like 
receptor (TLR) 4 gene also have been associated with differential severity of illness.107 
RSV strain differences are a determinant of disease phenotypes and severity. Very 
different antigenic subgroup A viruses co-circulate each year, and the response to 
infection with different viral strains is fundamentally different in genetically identical 
mice.108 One of the major criticisms about the mouse model of RSV infection is that it 
does not represent the pathologic features seem in humans with high fidelity, namely 
that airway obstruction resulting from mucus production present in humans is not 
present in the mouse. Therefore, it is critical to use clinical strains that recapitulate key 
features of RSV disease in humans when studying RSV pathology in mice. 
Unfortunately, there are no interventions that significantly improve clinical 
outcomes for RSV bronchiolitis once infection has occurred. Randomized, prospective 
clinical trials of the anti-viral ribavirin in infant RSV bronchiolitis have yielded 
disappointing results,109,110 while studies examining the effect of corticosteroid and 
bronchodilator therapy have routinely resulted in no improvement compared to 
placebo.111–113 Prophylactic administration of the anti-RSV monoclonal antibody 
palivizumab to high-risk populations, such as premature infants and those with 
underlying cardiopulmonary disease, significantly reduced hospitalizations.114,115 Two 
studies suggest that prevention of severe RSV bronchiolitis with prophylactic 
administration of RSV immune globulin may impact the subsequent development of 
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asthma. A prospective multicenter, matched, double cohort study of premature infants 
less than 36 weeks gestation conducted in 27 centers in Europe and Canada revealed 
that nonatopic subjects who received palivizumab in the first year of life had an 80% 
decrease in the relative risk of recurrent wheezing through ages 2 to 5 compared to 
those of gestational age-matched controls.116 These results not only showed a 
protective effect of an anti-RSV monoclonal antibody in the later development of 
wheezing, but also suggested that RSV predisposes to recurrent wheezing in an atopy-
independent mechanism. Another study also suggests that preventing RSV bronchiolitis 
significantly diminishes the likelihood of asthma exacerbations and improves pulmonary 
function later in childhood. In a retrospective case-control study of children at high risk 
of respiratory disease, prophylaxis with RSV immune globulin during infancy 
significantly reduced the risk of an asthma attack in the year prior to the children being 
studied at age 7 to 10 years of age.117 In addition, there was a significant improvement 
in the ratio of forced expiratory volume in 1 second to forced viral capacity (FEV1/FVC), 
a measure of airway obstruction.117 These studies suggest that preventing severe RSV 
bronchiolitis may reduce the incidence of asthma in childhood. Two recent trials of 
antiviral RSV therapies have shown early results of more rapid viral clearance and 
partial attenuation of disease severity.118,119 These promising results highlight the 
importance of developing anti-inflammatory therapies that can be used in combination 
with anti-virals to achieve complete disease abrogation. 
 
Pathways of immune modulators of inflammation  
STAT6 signaling  
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The Th2 cytokines IL-4 and IL-13 utilize the STAT6 signaling pathway. IL-4 is the 
most important cytokine in Th2 differentiation and inhibits Th1 and Th17 differentiation. 
IL-4 suppression of Th1 development is mediated by GATA-3; this transcription factor is 
induced by IL-4 and also acts as the master regulator of Th2 differentiation.120 IL-4 
inhibits Th1 differentiation by decreasing IL-12R expression.121 IL-4, as well as IL-13, 
induces goblet cell metaplasia and mucus expression, alternative macrophage 
activation, and airway remodeling.122 IL-4 can signal through either the type I IL-4R 
which consists of IL-4Rα and the common γ chain, or the type II IL-4R which consists of 
IL-4Rα and IL-13Rα (Figure 1.5).123,124 Low concentrations of IL-4 are presumed to 
signal more effectively through the type II IL-4Rα than do low concentrations of IL-13. 
IL-4 binds to the IL-4Rα portion of the IL-4 heterodimer receptor with high affinity and 
causes activation of JAK1 and JAK3 leading to the phosphorylation and dimerization of 
the transcription factor STAT6 at the Tyr-641 residue.125,126 STAT6 is then able to 
translocate into the nucleus and turn on the transcription of STAT6-dependent genes. 
IL-4 suppression of IL-17A protein expression from Th17 cells is dependent on 
STAT6.127–129 IL-4 attenuates IL-17A protein expression by T cells.127–129 
 In addition to dupilumub and lebrikizumab, the IL-4Rα antibody, AMG 317, was 
recently reported to reduce IgE levels and the number of exacerbations in patients with 
moderate-to-severe asthma.130 The rhIL-4 variant, pitrakinra, which competitively 
inhibits IL-4 or IL-13 binding to IL-4Rα, resulted in a smaller decrease in FEV1 in 
patients with mild asthma.131 
 
 20 
 
Figure 1.5. STAT6 signaling. IL-4R activation activates JAK1 and JAK3 leading to the 
phosphorylation and dimerization of STAT6, which then translocates into the nucleus to 
turn on the transcription of STAT6-dependent genes. 
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PGI2 signaling  
One of the primary byproducts of acute allergic (IgE-mediated type I 
hypersensitivity) reactions is the generation of arachidonic acid from inflammatory cell 
membranes.132 The cyclooxygenase family of enzymes convert arachidonic acid 
substrate into prostaglandins and thromboxane. Arachidonic acid can also be 
metabolized by the enzyme 5-lipoxygenase to produce the leukotrienes.132 In particular, 
prostaglandins influence many important inflammatory processes.132 These mediators 
are produced by the phospholipase A2 cleavage of arachidonic acid from membrane 
phospholipids, followed by the COX conversion of arachidonic acid to prostaglandin H2 
(PGH2). PGH2 may then be converted by specific synthases or isomerases to either 
prostaglandin D2 (PGD2), prostaglandin F2 (PGF2), prostaglandin I2 (PGI2), 
prostaglandin E2 (PGE2), or thromboxane (Figure 1.6).
132 The prostanoids have diverse 
effects on the inflammatory cascade and are presumed to have modulatory roles in 
asthma.133,134 PGD2 is increased in the bronchoalveolar lavage (BAL) fluid of asthmatic 
subjects, while both PGD2 and PGF2 contract human airways smooth muscle in vitro 
and are potent bronchoconstrictors in vivo.135,136 Thromboxane also causes human 
airway smooth muscle contraction in vitro.137 PGE2 inhalation inhibits the pulmonary 
immediate and late phase responses to inhaled allergen.138,139 Compared to vehicle 
inhalation, inhaled PGE2 also decreases the change in methacholine airway reactivity 
and reduces the number of eosinophils after inhaled allergen challenge.138 Interestingly, 
although PGE2 has significant effects on pulmonary function in challenge models, it has 
no effect on baseline FEV1 or methacholine reactivity.
139 The results from these studies 
suggest that PGE2 has a greater immunomodulatory effect than direct effect on airway  
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Figure 1.6. PGI2 production and signaling. PGI2 is one of 5 primary prostaglandins 
generated by COX-mediated conversion of arachidonic acid. PGI2 signals through the 
seven transmembrane G protein-coupled receptor IP. Adapted from Stitham et al., Front 
Pharmacol 2011.140 
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caliber. This notion is supported by the fact that PGE2 inhalation prior to segmental 
allergen challenge significantly reduced the BAL levels of PGD2, an important product of 
mast cell degranulation, and the cysteinyl leukotrienes.141 Thus, these prostanoids have 
important immunomodulatory effects in allergic lung inflammation and asthma. 
PGI2 is a prominent COX product produced in the lung as a result of antigen 
challenge. PGI2 and PGD2 were the predominant COX products produced in antigen-
induced anaphylactic reactions of human lung parenchyma, on the order of 3- to 7-times 
greater concentrations than of the other prostanoids.142 The PGI2 metabolite 6-keto-
PGF1 was produced in concentrations two-to-three-fold higher than all the other 
prostanoids in both airway and subpleural lung fragments in an in vitro anaphylaxis 
assay of passively sensitized human lung.143 Plasma 6-keto-PGF1 was also increased 
following antigen challenge in which asthmatic subjects were pretreated with 
indomethacin.144 Thus, PGI2 is produced in abundance in allergic inflammatory 
responses in the lung. For many years, PGI2 was thought to primarily have effects on 
vascular tissues as these were the tissues that produced PGI2 in greatest abundance 
and were the ones that most highly expressed IP. PGI2 production is highest in the 
heart, lung, smooth muscle, kidney, and ovary and is expressed at moderate levels in 
the brain, pancreas, and prostate.145 Low level production of PGI2 has been reported in 
the placenta, spleen, and leukocytes.145 One study also reported that PGI2 was 
produced by the human alveolar basal epithelial cell line A549.146 In these experiments, 
in vitro basal level expression of the PGI2 metabolite 6-keto-PGF1α was approximately 
25 ng/106 A549 cells and this increased to 75 ng/106 A549 cells after culture with IL-1β 
for 24 hours.146 Therefore, human alveolar basal epithelial cells produce PGI2 which 
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may regulate immune responses in the lung. IP is a member of a family of eight 
prostanoid receptors that have conserved homology in mammals, including mice and 
humans, through which PGI2 and PGI2 analogs signal.
147 All of the prostanoid receptors 
are encoded on different genes. IP is a G protein-coupled rhodopsin-type receptor that 
has seven transmembrane domains. Binding of PGI2 to its receptor activates adenylate 
cyclase via Gs in a dose-dependent manner, increasing the production of cyclic 
adenosine monophosphate (cAMP).148 This increase in intracellular cAMP mediates 
PGI2's effect of inhibiting platelet aggregation, and dispersing existing platelet 
aggregates both in vitro and in human circulation.148 Northern blot analysis reveals that 
IP mRNA is expressed to the greatest degree in the thymus, while high level of IP 
mRNA expression is also found in spleen, heart, lung, and neurones in the dorsal root 
ganglia. IP is also expressed in T cells of mice, along with the PGE2 receptor (EP) 
subtypes and the thromboxane receptor (TP).149 IP has also been found in kidney 
smooth muscle and epithelial cells.150 
The Food and Drug Administration (FDA) has approved epoprostenol (the 
sodium salt of PGI2), treprostinil, and iloprost for treatment of primary pulmonary 
hypertension on the basis of their vasodilatory effects. Epoprostenol has also been used 
safely and effectively in patients with other causes of pulmonary hypertension, including 
scleroderma, systemic lupus erythematosus, congenital heart disease, HIV, and 
Gaucher’s disease.151 Analogs, such as treprostinil, cicaprost, and iloprost, are used 
because the half-life of PGI2 is extremely short in circulation (3-5 minutes). Epoprostenol 
is administered intravenously and is converted quickly to stable metabolites through 
rapid hydrolysis in the circulation and extensive metabolism in the liver.152 Treprostinil 
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can be administered either intravenously or directly to the lungs by inhaler, and iloprost 
is inhaled.  Treprostinil has similar physiologic properties to epoprostenol, but has the 
advantage in that the half-life is significantly longer at three hours. Inhaled treprostinil, 
administered four times a day, has recently been shown to be effective in the treatment 
of severe pulmonary hypertension.153 Iloprost has a half-life of approximately 20 
minutes and because of its short duration of action it must be inhaled 6-9 times per day. 
Therefore, newer PGI2 analogs offer a significant pharmacologic, and potentially 
therapeutic, advantage over epoprostenol. 
PGI2 modulates the intersection of innate and adaptive immunity. The PGI2 
analogs iloprost, cicaprost, and treprostinil differentially modulated activation-induced 
responses of murine bone marrow-derived dendritic cells (BMDC) in an IP-dependent 
manner.154 These PGI2 analogs decreased activated-induced BMDC production of the 
proinflammatory cytokines IL-12, TNF-α, IL-1α, and IL-6, while also inhibiting the 
expression of chemokines known to be important in recruitment of inflammatory cells to 
the lung, including MIP-1α and MCP-1.154 While reducing these pro-inflammatory 
cytokines and chemokines, PGI2 analogs increased the production of the anti-
inflammatory cytokine IL-10 by BMDCs, an important finding since DC production of IL-
10 has been shown to promote the induction of CD4+ CD25+ Foxp3+ T regulatory cells 
(Tregs).155 The modulatory effect of PGI2 analogs on BMDCs was associated with IP-
dependent upregulation of intracellular cAMP and down-regulation of NF-κB activity.154 
Iloprost and cicaprost also suppressed activated BMDC expression of CD86, CD40, and 
MHC class II molecules and inhibited the ability of BMDCs to stimulate antigen-specific 
CD4 T cell proliferation and production of the Th2 cytokines IL-5 and IL-13. These 
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findings suggest that PGI2 signaling through the IP may exert anti-inflammatory effects 
by acting on DC.154 PGI2 analogs potently modulate CD4 T cell function. Purified CD4 T 
cells were activated with anti-CD3 and anti-CD28 antibodies under Th1 and Th2 
polarizing conditions for 4 days and restimulated the T cells with anti-CD3 in the 
presence of PGI2 analogs for 2 days. Cicaprost and iloprost inhibited the production of 
Th1 cytokines (IFN-γ) and Th2 cytokines (IL-4 and IL-13) in a dose-dependent pattern. 
The inhibitory effect was partially dependent on the IP receptor signaling and was also 
correlated with elevated intracellular cAMP and down-regulated NF-κB activity. PGI2 
analogs have potent anti-inflammatory effects on activated DCs and previously 
activated and differentiated CD4 T cells in vitro. 
PGI2 and signaling through IP downregulates allergic inflammation in mouse 
models of ovalbumin-induced allergic inflammation. Acute ovalbumin-induced allergic 
inflammation, as defined by lung production of IL-4 and IL-5, serum antigen-specific and 
total IgE levels, and airway leukocyte accumulation were increased in IP-/- mice 
compared to wild type mice.156 In a model of chronic ovalbumin airway exposure, IP-/- 
mice had greater airway eosinophils and lymphocytes, Th2 cytokine levels, and 
hydroxyproline concentrations compared to wild type mice.157 In addition, treatment of 
polarized murine Th2 CD4+ T lymphocytes with a stable PGI2 analog augmented IL-10 
production, which is conjectured to restrain allergic responses.158 Intranasal 
administration of the PGI2 analog iloprost protected against the development of allergic 
lung inflammation and methacholine-induced airway responsiveness (AR).159 Thus, 
published work indicates that signaling through IP downregulates allergic inflammation 
in the lung and improves lung physiology. Finally, absence of PGI2 signaling during 
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sensitization broke immune tolerance elicited by prior mucosal allergen exposure.160 
Another study revealed that endogenous PGI2 signaling through IP regulates lung 
disease expression in a model different from allergic inflammation. Mice that lacked the 
ability to signal through IP had augmented inflammatory and physiologic changes 
compared to WT mice in the model of bleomycin-induced fibrosis.161  
 
GLP-1R signaling  
 Incretins are gut hormones that potentiate insulin secretion after meal ingestion 
in a glucose-dependent manner. While the insulinotropic properties of incretins were 
identified more than 25 years ago, new actions of incretin hormones continue to be 
identified. The two best-studied incretins, glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1), exert their actions through distinct G-
protein-coupled receptors. Two strategies encompassing potentiation of incretin 
receptor signaling have been pursued for the treatment of type 2 diabetes. Inhibition of 
dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for N-terminal cleavage and 
inactivation of GIP and GLP-1, has been achieved through the use of orally available 
medications with high selectivity for the catalytic subunit of DPP-4. A second class of 
incretin-based therapies is comprised of injectable GLP-1R agonists that exhibit 
structural homology to human GLP-1 or to nonmammalian GLP-1R agonists.  
GLP-1 is synthesized by and secreted from enteroendocrine L cells present 
throughout the small and large intestines.162 GLP-1 is a product of post-translational 
processing of proglucagon by prohormone convertase 1/3.162 GLP-1 is also produced 
by the CNS, predominantly in brainstem nuclei with projections throughout the brain to 
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regulate metabolic, cardiovascular, and neuroprotective activities.163 For instance, 
neuronal GLP-1R signaling reduced hypothalamic reactive oxygen species 
production.164 Indeed, GLP-1 is a pleiotropic hormone with salutary action in multiple 
tissues and organs. The section of GLP-1 from enteroendocrine cells is stimulated by 
the gastrointestinal ingestion of nutrients such as carbohydrates, fats, and proteins.165 
Inflammatory signals also regulate GLP-1 synthesis, secretion, and action. For instance, 
the inflammatory cytokines IL-1, IL-6, and LPS increased plasma levels of GLP-1.166,167 
IL-6 may also be important for the synthesis, secretion, and anorectic actions of GLP-1 
in the brain, as almost 40% of the GLP-1+ neurons within the nucleus of the solitary 
tract express the IL-6 receptor α, and these PGDP+ neurons respond to exogenous IL-6 
with an increase in cytosolic Ca2+.168 The GLP-1R is a G protein coupled cytoplasmic 
membrane receptor. The GLP-1R is expressed on the beta cells of the pancreas, in the 
brain, on the myocardial cells of the heart, in the liver, and on airway epithelial cells in 
the lung. GLP-1 binding to its receptor results in activation of Gs which activates 
adenylate cyclase to increase cyclic AMP and activate the protein kinase A pathway 
(Figure 1.7). GLP-1R activation also results in β-arrestin-1 association with ERK1/2, 
leading to sustained activation and sequestration of phosphorylated ERK1/2 in the 
cytoplasm. In the pancreatic islets, GLP-1 potentiates insulin and suppresses glucagon 
secretion in a glucose-dependent fashion.169 It is this activity of GLP-1 that has been 
capitalized upon for the development of blockbuster diabetes drugs that target the GLP-
1 axis.170 There are several forms of these drugs that are commercially available 
including liraglutide, exenatide, and albiglutide. While GLP-1R signaling decreases 
serum glucose concentrations in people with diabetes, it does not stimulate insulin  
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Figure 1.7. GLP-1 signaling. GLP-1 is one of two well-studied incretin hormones. GLP-
1 signals through the seven transmembrane receptor GLP-1R which results in Gs 
activation, adenylate cyclase activation, increased cyclic AMP, and activation of the 
protein kinase A pathway. GLP-1R activation also signals through the ERK pathway.  
 30 
secretion or decrease glucose levels in people without diabetes under euglycemic 
conditions, an important safety component of these therapies.170  
In addition to its metabolic effects, GLP-1R signaling also has immunoregulatory 
functions that decrease inflammatory responses. GLP-1R is expressed on a variety of 
hematopoetic cells, including thymocytes, splenocytes, and T regulatory cells (Tregs).171 
A GLP-1R agonist decreases human CD4+ cell migration to both RANTES and CXCL12  
(SDF-1). CXCL12 is strongly chemotactic for lymphocytes.172 GLP-1R signaling 
increases levels of cAMP and significantly inhibits IL-4 production by human invariant 
natural killer (iNKT) cells.173 GLP-1R signaling decreases TNF-α-induced reactive 
oxygen species (ROS) production, protein kinase C activation, and NF-κB activation in 
primary human endothelial cells.174 GLP-1R-deficient mice have decreased numbers of 
T regulatory cells, suggesting that GLP-1 receptor signaling promotes Treg 
development.171 The intestinal mucosa of GLP-1R-deficient mice also exhibited 
dysregulated anti-inflammatory gene profiles, which was reversed by the reconstitution 
of GLP-1R+ intestinal intraepithelial lymphocytes through bone marrow 
transplantation.175  
Anti-inflammatory actions of GLP-1R agonists have also been described in 
diabetes, psoriasis, cardiovascular disease, and chronic lung disease such as allergic 
airway inflammation and bleomycin-induced fibrosis. Activation of the GLP-1R in T2D 
patients significantly reduced serum levels of the pro-inflammatory cytokines TNF-α, IL-
1β, and IL-6.176 GLP-1 infusion decreased circulating levels of IL-6 during normal or 
increased insulinemia in the presence of euglycemia, demonstrating that GLP-1 exerts 
anti-inflammatory actions independent of changes in insulin levels.177 A recent 
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randomized control trial demonstrated the effectiveness of liraglutide in reducing rates 
of first occurrence of death from cardiovascular disease, nonfatal myocardial infarction, 
or nonfatal stroke in patients with Type II diabetes presenting with a high risk for 
cardiovascular disease.178 The number of first microvascular events, largely reflecting a 
reduction in kidney disease, was also significantly lower in liraglutide-treated subjects. 
In addition, the low-frequency missense GLP1R variant rs10305492 was associated 
with significantly lower risk of coronary artery disease independent of any changes in 
blood pressure or body mass index.179 A recent prospective cohort study evaluated the 
effectiveness of liraglutide in reducing disease severity in patients with psoriasis and 
Type II diabetes.180 Patients on liraglutide therapy had decreased Psoriasis Area and 
Severity Index (PASI) scores. GLP-1R signaling also decreased inflammatory cell 
infiltration and goblet cell hyperplasia in models of chronic lung inflammation such as 
allergic airway inflammation and bleomycin-induced fibrosis.181,182 
 
Significance of these studies 
Chapter II demonstrates the ability of STAT6 to regulate innate γδ17 cell immune 
responses. STAT6 suppression of γδ17 cell function may provide one explanation for 
why asthmatic patients have significantly greater risk for invasive bacterial disease, 
including pneumonia, than nonasthmatic subjects. Chapter III demonstrates that a GLP-
1R agonist, an FDA-approved agent currently used for Type II Diabetes, attenuates the 
type 2 immune response to RSV and attenuates RSV illness. The current availability of 
GLP-1R agonists for human treatment highlights the clinical significance of these 
studies as this therapy could be immediately transferrable to RSV disease. Chapter IV 
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demonstrates that PGI2, an FDA-approved agent currently used for pulmonary 
hypertension, protects against autoimmunity; enhances Treg stability and function; 
renders T effector cells more susceptible to Treg- mediated suppression; and promotes 
iTreg differentiation. PGI2 may therefore represent a novel treatment strategy for 
diseases that result from Treg dysregulation. 
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CHAPTER II 
 
STAT6 SIGNALING ATTENUATES IL-17-PRODUCING γδT CELLS DURING ACUTE 
KLEBSIELLA PNEUMONIAE INFECTION 
 
Introduction 
γδ T cells compose approximately 50% of the intraepithelial lymphocyte 
population and constitute a critical first line of defense against bacterial and fungal 
pathogens.183 In contrast with adaptive αβ T cells, γδ T cells are capable of immediate 
cytokine release, providing an initial innate layer of protection at mucosal surfaces while 
influencing the development of subsequent adaptive responses.80,184 γδ17 cells are a 
subset of γδ T cells that produce large quantities of IL-17A, a cytokine crucial to anti-
bacterial and anti-fungal defense.69 γδ17 cells also produce high levels of IL-17A in 
various models of inflammation and autoimmunity, including experimental autoimmune 
encephalitis, ischemic brain injury, and psoriasis.80,184–187 While these data highlight the 
importance of understanding how γδ17 cell function is regulated, this process remains 
poorly understood.  
γδ17 cell function is controlled by multiple immune cell populations and soluble 
molecules, particularly cytokines. Within 4-8 hours in the presence of the inflammatory 
cytokines IL-23 and IL-1β, γδ17 cells secrete IL-17A without the need for TCR 
engagement.80 γδ17 cells constitutively express IL-23R and IL-1R1, providing for an 
efficient mechanism to induce rapid effector cytokine production. A recent study showed 
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that the serine/threonine kinase Sgk1 is a novel, critical regulator of IL-23R 
expression.188 
Studies from our group and others have established that STAT6 negatively 
regulates IL-17A expression in Th17 cells.127–129,189,190 By extension, we hypothesized 
that STAT6 also inhibits innate γδ17 cell cytokine secretion. STAT6 is a transcription 
factor important for Th2 differentiation, inhibiting Th1 differentiation, and activating the B 
cell response.191 IL-4 signals through both the type I IL-4R, which consists of IL-4Rα 
and the common γ chain, and the type II IL-4R, which consists of IL-4Rα and IL-13Rα, 
while IL-13 signals through only the type II IL-4R.123,124 IL-4 binds to the IL-4Rα portion 
and IL-13 binds to the IL-13Rα subunit of the IL-4 heterodimer receptor with high 
affinity, leading to the phosphorylation of STAT6.125,126 STAT6 is expressed at high 
levels in the settings of parasitic infections and asthma,192 during which STAT6 induces 
Th2 differentiation, IgE antibody class switching, globlet cell metaplasia, alternative 
macrophage activation, mucus expression, and airway remodeling.193 Thus, STAT6 
attenuation of γδ17 cell function may impair host defenses against bacterial and fungal 
infections in people with asthma or parasitic infections. 
We found that γδ17 cells expressed the type I IL-4R, and that IL-4 increased 
STAT6 phosphorylation in γδ17 cells. Furthermore, IL-4 signaling attenuated γδ17 cell 
production of IL-17A and IL-17F. IL-4 also decreased γδ17 cell expression of the IL-23R 
as well as Sgk1. To determine whether STAT6 regulates γδ17 cell cytokine expression 
in vivo, we used a mouse model of Klebsiella pneumoniae lung infection in mice 
deficient in STAT6. We chose K. pneumoniae for our in vivo model since K. 
pneumoniae increases IL-17A expression and the number of γδ17 cells.65–
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67,70,76,77,194,195 We found a significant increase in γδ17 cell numbers in STAT6- deficient 
mice following acute lung infection with K. pneumoniae in vivo compared to WT mice. 
Together, these studies reveal that STAT6 negatively regulates γδ17 cells, a cell 
population that plays a front line role in mucosal immunity.  
 
Materials and Methods 
Mice 
8- to 12-week old female BALB/c mice were purchased from Charles River 
Laboratories (Wilmington, MA). STAT6 KO, IL-4 KO, and IL-13 KO mice on a BALB/c 
background were purchased from The Jackson Laboratory, and breeding colonies were 
established (Bar Harbor, ME). In caring for the animals, investigators adhered to the 
revised 1996 Guide for the Care and Use of Laboratory Animals prepared by the 
Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal 
Resources, National Research Council. Experiments were approved by the Vanderbilt 
Institutional Animal Care and Use Committee. 
 
T cell isolation and culture 
γδ T cells from the spleens of BALB/c WT mice were enriched using anti-murine 
γδ TCR magnetic microbeads (Miltenyi Biotec, Auburn, CA). γδ T cells were purified by 
flow cytometry by blocking with anti-FcR antibody (2.4G2, BD Biosciences, San Jose, 
CA), and using propidium iodide viability stain and surface markers against CD3 (145-
2C11) and γδ TCR (GL3, BD Biosciences). The purified CD3+γδ TCR+ cells were 
resuspended at 3 x 105 cells/mL and were induced to produce IL-17A using IL-1β (10 
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ng/mL) and IL-23 (10 ng/mL) in 96-well plates for 3 days.80 CD3+ T cells were activated 
with plate-bound anti-CD3 (5 ug/mL) and anti-CD28 (1 ug/mL). IL-4 (0.01-1 ng/mL) or 
IL-13 (10 ng/mL) was also added in select cultures. Mouse rIL-23 was purchased from 
R&D Systems. Mouse rIL-1β, mouse rIL-4, and  mouse rIL-13 were purchased from 
PeproTech (Rocky Hill, NJ). 
 
Cytokine measurements 
The secretion of cytokines (IL-17A, IL-17F, and IL-22) in cell culture supernatants 
were analyzed by commercially available enzyme-linked immunoabsorbent assay 
(ELISA) kits (R&D Systems, Minneapolis, MN) following the manufacturer’s instructions. 
Any value below the lower limit of detection was assigned half the value of the lowest 
detectable standard for statistical comparisons. 
 
Quantitative PCR 
Total RNA was isolated using a Qiagen RNAesy micro kit (Valencia, CA) and 
cDNA was generated. A two-step real-time PCR assay using SYBR green mix (Bio-
Rad, Hercules, CA) was used to detect IL-23R, Sgk1, Foxo1, MyD88, TRAF6 
(proprietary information available by Qiagen), RORγT, and AhR as previously described 
196, and normalized to GAPDH. Primer sequences were as follows: IL-23R: forward, 5’-
GGTCCAAGCTGTCAATTCCCTAGG-3’, reverse, 5’-
AGCCCTGGAAATGATGGACGCA-3’; RORγT: forward, 5’-
GCGGCTTTCAGGCTTCATGGAG-3’, reverse, 5’-GGGCGCTGAGGAAGTGGGAAAA-
3’; AhR: forward, 5’-CGGGGTACCAGTTCATCCACGCT-3’, reverse, 5’-
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GCAAACATGAAGGGCAGCGACGT-3’; GAPDH: forward, 5’-
GGCCCCTCTGGAAAGCTGTGG-3’, reverse, 5’-CCCGGCATCGAAGGTGGAAGA-3’. 
Klebsiella infection 
WT and STAT6 KO mice were anesthetized with ketamine/xylazine and then 
infected with 0.3-1x103 CFU of serotype 2 K. pneumoniae (ATCC 43816) in 50 μL PBS 
or 50 μL PBS alone by retropharyngeal instillation. Bacterial stocks of K. pneumoniae 
were inoculated into 100 ml of tryptic soy broth (TSB) and incubated for 18 h at 37°C 
and 225 rpm. One milliliter of this culture was transferred to 100 ml of TSB, and bacteria 
were grown to mid-log phase for 2 h at 37°C. Bacteria were pelleted, washed in sterile 
PBS, and diluted to the appropriate concentration as previously described.195,197 The 
inoculum concentration was verified by serial dilution in PBS, plating on tryptic soy agar 
(TSA), and visual determination of colony counts. 
 
Harvest and bacterial quantitation 
Lungs were harvested 36 hours after K. pneumoniae infection. Mice were 
euthanized by intraperitoneal injection of pentobarbital sodium (Vortech 
Pharmaceuticals, Dearborn, MI). The right lung was harvested into 1 mL of RPMI 
medium and analyzed by flow cytometry. The left lung was harvested into 1mL of sterile 
PBS and organs were homogenized. Serial dilutions in PBS were plated onto TSA, 
grown overnight at 37°C, and colonies were counted.  
 
Flow cytometry 
 CD3+ T and γδ17 cells were harvested and cells were blocked with anti- 
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antibody (BD Biosciences) and in select experiments stained with surface markers 
against CD3, γδ TCR, IL-4Rα (mIL4R-M1) or IgG2a, κ isotype control (BR2a), and 
common γ-chain (TUGm) or IgG2b, κ isotype control (27-35, BD Biosciences). For 
experiments examining STAT6 phosphorylation, select wells were stimulated with IL-4 
(10ng/ml) for one hour. Cells were blocked with normal mouse serum (eBioscience, San 
Diego, CA) and stained with surface markers against CD3 and γδ TCR. Cells were then 
permeabolized and fixed with 4% paraformaldehyde and methanol, respectively, 
washed thoroughly, and stained for phospho-STAT6 (J71-773.58.11) or IgG1κ isotype 
control (MOPC-31C, BD Biosciences). 
Lungs were harvested, minced, and digested in RPMI media containing 5% FBS, 
1 mg/mL collagenase type IV, and 0.02 mg/mL DNase I for 40 min at 37°C. The 
digestion was stopped with 100 μl of 0.5 M EDTA, and a single cell suspension was 
generated by straining these digestions through a 70-μm strainer. Cells were 
restimulated in RPMI media containing, 10% FBS, 50 ng/mL PMA  (Sigma-Aldrich, St. 
Louis, MO), 1 μM ionomycin (Sigma-Aldrich), and 0.07% GolgiStop (BD Biosciences) 
for 4 hours at 37°C and 5% CO2. Following restimulation, six million cells were stained 
with Live/Dead Blue (Life Technologies, Carlsbad, CA), blocked with anti-FcR antibody 
and surface markers against CD3, CD4 (H129.19), and γδ TCR. Cells were fixed/ 
permeabolized for 12 hours in Cytofix/ Cytoperm (BD Biosciences) and stained for IL-
17A (TC11-18H10, BD Bioscience). Anti-FcR antibody (BD Biosciences) was used to 
prevent nonspecific staining. A total of one million cells were analyzed using a LSR II 
flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Tree 
Star, Ashland, OR). 
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Statistical analyses 
Data are presented as mean ± SEM. For Figs. 1-4, data shown represent a 
combined analysis of cell culture wells from three independent experiments. For Fig. 5, 
data shown represent a combined analysis of individual mice from three independent 
experiments. Groups were compared using one-way analysis of variance (ANOVA) with 
Bonferroni's post-test or Student’s T-Test using Prism (version 5; GraphPad Software, 
San Diego, CA) with values being considered significant when p < 0.05. 
 
Results 
The type I IL-4R is expressed on γδ17 cells 
STAT6 negatively regulates IL-17A expression in CD4+ Th17 cells 127–129. By 
analogy, we hypothesized that γδ17 cells express the IL-4R, that IL-4 phosphorylates 
STAT6 in γδ T cells, and that IL-4 inhibits γδ17 cell cytokine secretion. To test this 
hypothesis, we first enriched γδ T cells from mouse spleens using a commercially 
available magnetic sorting kit (Miltenyi Biotec, Auburn, CA), and cell sorted for viable 
CD3+ γδ TCR+ cells (Figure 2.1). IL-4Rα was clearly detected on γδ T cells, and also 
on CD3+ T cells, which are known to express the IL-4R. Common γ-chain expression 
was also clearly detected on both γδ Tcells and CD3+ T cells (Figure 2.2A). As optimal 
IL-17A production from  γδ17 cells is induced following culture with both IL-1β and IL-
23,80 γδ T cells were cultured with IL-1β (10 ng/mL) and IL-23 (10 ng/mL) for three days. 
γδ17 cells or CD3+ T cells were then collected and IL-4R expression was examined by 
flow cytometry. Both IL-4R and common γ-chain were detected on induced γδ17 cells 
and activated CD3+ T cells (Figure 2.2B). Combined, these data demonstrate that γδ17   
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Figure 2.1. Isolated cells are CD3+ γδ TCR+. Representative plots after magnetic 
enrichment and during cell sorting are shown. Cells were gated on live cells.   
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Figure 2.2. IL-4Rα and common γ-chain are expressed in freshly isolated (A) and  
induced γδ17 (B). CD3+ T cells were stimulated with plate-bound anti-CD3 and anti-
CD28, and γδ T cells were induced to produce IL-17A with IL-1β and IL-23 for 3 days. 
Representative histograms of IL-4Rα and common γ-chain expression in CD3+ or γδ 
TCR+ cells compared with the isotype control. Histograms are representative of 3 
independent experiments; n = 5. 
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cells express the subunits of the type I IL-4R, suggesting a potential role for IL-4 in 
regulating these cells. 
 
IL-4 increases STAT6 phosphorylation in γδ17 cells 
Since the type I IL-4R was expressed on γδ17 cells, we hypothesized that the 
downstream transcription factor STAT6 is phosphorylated in the presence of IL-4. To 
test this hypothesis, we stimulated cultured γδ T cells or CD3+ T cells for one hour with 
IL-4 (0-10 ng/mL). CD3+ T cells stimulated with IL-4 had increased STAT6 
phosphorylation compared with that seen in CD3+ T cells with no IL-4 added. Similarly, 
γδ17 cells stimulated with IL-4 had increased STAT6 phosphorylation compared with 
that seen in γδ17 cells with no IL-4 added (Figure 2.3). These data demonstrate that a 
functional IL-4R is expressed by γδ17 cells. 
 
IL-4 but not IL-13, directly attenuates IL-17A production from γδ17 cells 
Based on the expression of a functional type I IL-4R on γδ17 cells and the known 
inhibitory effect of IL-4 on CD4+Th17 cells, we hypothesized that IL-4 directly decreases 
γδ17 cell cytokine secretion. Treatment of γδ17 cells with IL-4 in vitro (0.01-1 ng/mL) 
induced a significant dose-dependent decrease in γδ17 cell IL-17A protein expression 
(Figure 2.4A). IL-4 also attenuated γδ17 cell production of IL-17F (Figure 2.4B) in a 
dose-dependent manner. In three independent experiments, IL-4 also decreased γδ17 
cell IL-22 production in a dose-dependent manner, though the decrease in IL-22 
production was not statistically different when the three experiments were combined 
(data not shown).  
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Figure 2.3. IL-4 increases STAT6 phosphorylation in γδ T cells. CD3+ T cells or γδ 
T cells were stimulated with IL-4 (10 ng/ml) for 1 hour and examined for phospho-
STAT6 expression by flow cytometry. Representative histograms of phospho-STAT6 
expression in CD3+ (A) or γδ TCR+ (B) cells compared with untreated cells or isotype 
control. Histograms are representative of 3 independent experiments; n = 5. 
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Figure 2.4. IL-4 but not IL-13 attenuates IL-17A and IL-17F production from γδ17. 
γδ T cells were induced to produce IL-17, and IL-4 (0.01 ng/ml- 1ng/ml) and IL-13 
(10ng/ml) were added at the time of γδ T cell induction. IL-17A (A) IL-17F (B), or IL-13 
(C) protein expression in cultured supernatants were quantified by ELISA 3 days after 
induction. Data are combined from 3 independent experiments; n = 5; *p < 0.05, versus 
untreated γδ T cells (no IL-4), ANOVA (A-B), Student’s T-Test (C). 
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Since the Th2 cytokine IL-13 also negatively regulates IL-17A expression in 
CD4+ Th17 cells,128,198 we hypothesized that IL-13 also directly inhibits γδ17 cell 
cytokine secretion. However, we found that IL-17A expression was not statistically 
different between γδ17 cells treated with IL-13 and vehicle (Figure 2.4C). These data 
demonstrate that IL-4, but not IL-13, negatively regulated IL-17A and IL-17F protein 
expression from γδ17 cells at the time of induction. 
 
IL-4 decreases IL-23R and Sgk1 expression in γδ17 cells 
IL-4 reduced γδ17 cell IL-17A protein expression. Since IL-23 signals through the 
IL-23R to induce IL-17A production in γδ T cells, we hypothesized that IL-4 
administered during γδ17 cell induction decreases the expression of IL-23R and Sgk1, a 
critical regulator of IL-23R expression.188 We found that IL-4 decreased IL-23R mRNA 
expression in γδ17 cells three days following γδ17 cell induction (Figure 2.5A). We also 
found that γδ17 cells exposed to IL-4 had decreased Sgk1 mRNA expression one day 
following γδ17 cell induction (Figure 2.5B). The decreases in IL-23R and Sgk1 mRNA 
expression paralleled the IL-4-mediated decrease in γδ17 cell IL-17A production. Sgk1 
positively regulates IL-23R expression by deactivating Foxo1, a direct repressor of IL-
23R,188 however we did not find statistically significant differences in Foxo1 mRNA 
expression between IL-4 and vehicle- treated γδ17 cells in vitro (data not shown). We 
also determined mRNA expression for downstream components of the IL-1R signaling 
pathway, MyD88 and TRAF6, as well as for the canonical Th17-related transcription 
factors RORγT and AhR, which control γδ17 cell development.69,82 We did not find 
statistically significant differences in MyD88, TRAF6, RORγT, nor AhR mRNA  
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Figure 2.5. IL-4 signaling through IL-4R decreases IL-23R and Sgk1 mRNA 
expression in γδ17. Total RNA was isolated from γδ17 cells 3 (A) or 1 (B) days after 
induction. IL-23R (A) and Sgk1 (B) mRNA expression in γδ T cells induced in the 
presence of IL-4. All mRNA levels were assayed by quantitative real-time RT-PCR, with 
each sample normalized to GAPDH and relative expression compared with γδ T cells 
induced without IL-4 present. Data are combined from 3 independent experiments; n = 
5; *p < 0.05, versus untreated γδ T cells (no IL-4), ANOVA. 
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expression between IL-4 and vehicle- treated γδ17 cells in vitro (data not shown). 
Combined, these data suggest that IL-4 may attenuate γδ17 cell IL-17A production by 
decreasing IL-23R expression. 
 
STAT6 deficiency increases the number of mouse lung γδ17 cells in response to K. 
pneumoniae infection 
Based on our in vitro data that IL-4 inhibits IL-17A protein expression by γδ17 
cells, we hypothesized that STAT6 reduces the number of lung γδ17 cells in vivo. We 
chose mice deficient in STAT6, which is essential for signaling downstream of the IL-
4R. We infected mice with K. pneumoniae administered by retropharyngeal instillation 
and sacrificed the mice 36 hours later. We chose K. pneumoniae for our in vivo model 
because K. pneumoniae increases IL-17A expression and γδ17 cell numbers.65–67,194,195 
We chose this time course with the consideration that there was unlikely to be a robust 
adaptive immune response after only 36 hours of K. pneumoniae infection, and that 
instead this protocol would allow us to assess the innate response during which γδ T 
cells are important producers of IL-17A. We determined the number of lung γδ17 cells 
following 36 hours of K. pneumoniae infection. Following digestion of the lung, the 
number of γδ17 cells was determined following cell surface and intracellular cytokine 
staining in K. pneumoniae- infected WT and STAT6 KO mice (Figure 2.6A). There was 
a statistically significant two-fold increase in the percentage of lung γδ T cells that 
expressed IL-17A in the K. pneumoniae- infected STAT6 KO mice compared to the WT 
mice (Figure 2.6C). In addition, there was a statistically significant three-fold increase in 
the total numbers of lung γδ T cells that expressed IL-17A in the K. pneumoniae- 
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Figure 2.6. Increased airway γδ17 cell numbers in STAT6 KO compared to WT 
mice following acute lung infection with K. pneumoniae. Lung cells were 
restimulated with PMA and ionomycin in the presence of Golgi-stop. Representative 
contour plots that are CD3-gated (A and B). Percentages of IL-17A+CD3+γδ TCR+ or 
IL-17A+CD3+CD4+ cells (C). Total number of cells that are IL-17A+CD3+γδ TCR+ or 
IL-17A+CD3+CD4+ (D). Total cell numbers were calculated by multiplying the 
percentage of IL-17A+CD3+γδ TCR+ or IL-17A+CD3+CD4+ cells by the total cell 
number. Data are combined from 3 independent experiments; n = 15 mice for each 
group. *p < 0.05, ANOVA. 
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infected STAT6 KO mice compared to the WT mice (Figure 2.6D). In our experiments 
with K. pneumoniae, we were unable to detect IL-4 or IL-13 protein. However, our data 
would suggest that there was sufficient endogenous IL-4 and/ or IL-13 expression to 
decrease γδ17 cell numbers. To determine whether IL-4 or IL-13 alone had effects on 
γδ17 cells during acute K. pneumoniae infection, we also detected γδ17 cells in K. 
pneumoniae- infected IL-4 KO and IL-13 KO mice. The deletion of either IL-4 or IL-13 
alone did not have an effect on γδ17 cell numbers during acute K. pneumoniae infection 
(Figure 2.7). Therefore, STAT6 suppression of γδ17 cells during acute K. pneumoniae 
infection is likely due to the combined effect of both IL-4 and IL-13 signaling through 
STAT6. There were no significant differences in the percentage or number of γδ17 cells 
in STAT6 KO, IL-4 KO, or IL-13 KO mice compared to WT mice at a baseline level in 
mice not infected with K. pneumoniae (Figure 2.8). 
We also used flow cytometry to determine the number of CD4+ T cells producing 
IL-17A in our model (Figure 2.6B). We found that there was a two-fold increase in γδ17 
cells compared to CD4+ IL-17A-expressing cells in WT mice, and a six-fold increase in 
γδ17 cells compared to CD4+ IL-17A-expressing cells in STAT6 mice, showing that 
γδ17 cells were more abundant than CD4+IL-17A+ cells at this time point after infection 
in both WT and STAT6 KO mice (Figure 2.6D). The percentage of CD4+IL-17A+ cells 
was not statistically different between the K. pneumoniae- infected STAT6 KO and WT 
mice. Similarly, the number of CD4+IL-17A+ cells was not statistically different between 
the K. pneumoniae- infected STAT6 KO and WT mice (Figure 2.6D). Lung K. 
pneumoniae burden did not differ significantly between the K. pneumoniae- infected 
STAT6 KO and WT mice (data not shown). These results reveal that endogenous   
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Figure 2.7. Increased airway γδ17 cell numbers in STAT6 KO compared to WT 
mice following acute lung infection with K. pneumoniae. Lung cells were 
restimulated with PMA and ionomycin in the presence of Golgi-stop. Percentages of IL-
17A+CD3+γδ TCR+ (A). Total number of cells that are IL-17A+CD3+γδ TCR+ (B). Total 
cell numbers were calculated by multiplying the percentage of IL-17A+CD3+γδ TCR+ 
cells by the total cell number. Data are representative of 2 independent experiments; n 
= 8-10 mice for each group. *p < 0.05, ANOVA. 
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Figure 2.8. Baseline γδ17 cell numbers in STAT6 KO compared to WT mice. Lung 
cells were restimulated with PMA and ionomycin in the presence of Golgi-stop. 
Percentages of IL-17A+CD3+γδ TCR+ (A). Total number of cells that are IL-
17A+CD3+γδ TCR+ (B). Total cell numbers were calculated by multiplying the 
percentage of IL-17A+CD3+γδ TCR+ cells by the total cell number. Data are 
representative of 2 independent experiments. n = 10 mice for each group. ANOVA. 
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STAT6 signaling significantly inhibited the number of γδ17 cells in response to K. 
pneumoniae infection. The results also support that γδ17 cells, and not CD4+ cells, 
were the primary producers of IL-17A in response to this acute K. pneumoniae infection 
protocol. 
 
Discussion 
Our data are the first to demonstrate that γδ17 cells expressed both IL-4Rα and 
common γ chain, the heterodimeric components of the type I IL-4R, and that γδ17 cell 
expression of the type I IL-4R was functional, as IL-4 induced STAT6 phosphorylation in 
γδ T cells. IL-4 negatively regulated γδ17 cell production of IL-17A and IL-17F in vitro. 
IL-4-mediated attenuation of IL-17A production also paralleled decreases in IL-23R and 
Sgk1 expression. Since IL-23 is required for γδ17 cell production of IL-17, IL-4 may 
inhibit γδ17 cell function by decreasing IL-23R expression. This mechanism of γδ17 cell 
inhibition via IL-23R downregulation could mirror how IL-4 inhibits Th1 differentiation by 
decreasing IL-12R expression.121 The serine/ threonine kinase, Sgk1, was recently 
found to stabilize the Th17 cell phenotype by stabilizing IL-23R expression.188 We found 
that Sgk1 expression was decreased one day following γδ17 cell induction in culture, 
while IL-23R expression was decreased three days following γδ17 cell induction. 
Therefore, the observed IL-4-mediated decreases in IL-17A production could potentially 
be caused by decreased Sgk1 expression leading to destabilized IL-23R expression on 
γδ17 cells. 
An important finding in this report is that IL-4 and IL-13 differentially regulate 
CD4+ Th17 and γδ17 cell cytokine production. While a concentration as low as 0.1 
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ng/mL of IL-4 significantly decreased γδ17 cell IL-17A production, 100 times more IL-4 
is required to inhibit IL-17A production from Th17 cells.128 This indicates that the IL-4R 
on γδ17 cells is either more sensitive to the presence of IL-4 or more robustly induces 
downstream IL-4 signaling compared to the IL-4R on Th17 cells. While IL-4 directly 
inhibited IL-17A production from both Th17 and γδ17 cells, IL-13directly inhibited IL-17A 
production from Th17 cells but not from γδ17 cells.128,198 These results suggest that IL-4 
and IL-13 may use different mechanisms to inhibit γδ17 cells. 
We show that STAT6 signaling reduced lung γδ17 cell numbers in vivo. IL-4 binds 
to the IL-4Rα portion and IL-13 binds to the IL-13 α subunit of the IL-4 receptor, leading 
to the phosphorylation of STAT6. STAT6 deficiency increased both the percentage of 
lung γδ T cells that expressed IL-17A as well as the total number of γδ T cells in the 
lung that expressed IL-17A protein in response to acute K. pneumoniae infection. We 
confirmed that γδ17 cells, and not CD4+ T cells, were the major contributors of IL-17A 
in our model of acute K. pneumoniae infection. To our knowledge, there are no studies 
in which CD4+ T cells or IL-13 has been depleted during acute K. pneumoniae infection 
to determine whether this cell type or cytokine has a role during the immune response. 
IL-13 did not have a direct effect on γδ17 cell cytokine production in vitro. However, the 
genetic deletion of either IL-4 or IL-13 alone did not have an effect on γδ17 cell numbers 
during acute K. pneumoniae infection. Therefore, STAT6 suppression of γδ17 cells 
during acute K. pneumoniae infection is likely due to the combined effect of both IL-4 
and IL-13 signaling through STAT6. IL-13 may regulate γδ17 cells indirectly, as IL-13 
suppresses dendritic cell expression of γδ17 cell-promoting factors such as IL-1β and 
IL-23.199 
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Future lines of research should address STAT6 downregulation of γδ17 cell 
function in other tissues and in additional models of immune-mediated inflammation and 
infection. Tissue localization dictates γδ TCR diversity.200 Similarly, γδ17 cells may 
differentially express the IL-4R and STAT6 may distinctly regulate γδ17 cell cytokine 
production in other sites where γδ T cells are prevalent, such as in the gut or skin. 
Increasing STAT6 activity could represent an immunotherapeutic strategy to treat γδ17-
mediated diseases, such as psoriasis and multiple sclerosis, by decreasing 
inflammatory IL-17A production.201,202 In contrast, STAT6 is expressed at high levels in 
patients with asthma,193 and phase II randomized clinical trials have investigated the 
effects of blocking IL-4 and IL-13 signaling. The IL-4Rα antibody, AMG 317, reduced 
IgE levels and the number of exacerbations in patients with moderate-to-severe 
asthma.130 The rhIL-4 variant, pitrakinra, which competitively inhibits IL-4 or IL-13 
binding to IL-4Rα, resulted in a smaller decrease in FEV1 in patients with mild 
asthma.131 However, the impact of these anti-IL-4 and anti-IL-13 therapies on γδ17 cells 
is unknown. Based on the findings of our study, anti-IL-4 and anti-IL-13 therapies used 
to treat asthmatic patients could potentially have the adverse effect of exacerbating co-
existing immune-mediated inflammatory diseases, such as multiple sclerosis, in these 
patients. Blocking IL-4 and IL-13 activity could also decrease infection severity from 
pathogens for which strong, early γδ17 cell responses are critical for immunity. During 
the immune response to pathogens such as Mycobacterium tuberculosis, 
Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, and Candida 
albicans,71,73–75 γδ17 cells stimulated neutrophil recruitment, antibacterial peptide 
production, and maintenance of epithelial barriers.78 Notably, people with asthma, who 
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express high levels of STAT6,203 are at increased risk for invasive bacterial infections 
and bacterial pneumonia.53–56 However, the mechanisms by which asthma impairs host 
defense against bacterial infection are unknown. Our results may provide one 
explanation for why asthmatic subjects have a significantly greater risk of invasive 
bacterial disease than nonasthmatic subjects. 
 In summary, we are the first to show that γδ17 cells express a functional IL-4R, 
and demonstrate a novel role for the transcription factor STAT6 in negatively regulating 
γδ17 IL-17A production. These findings have significant and broad implications for how 
γδ17 cells, an important cell population that plays a front-line role in mucosal immunity, 
are regulated in the spleen and lung. 
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CHAPTER III 
 
GLP-1R SIGNALING ATTENUATES RSV-INDUCED TYPE 2 RESPONSES AND 
IMMUNOPATHOLOGY 
 
Introduction 
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization.204 
RSV induces bronchiolitis and viral pneumonia, and in severe cases, can lead to death. 
RSV is the second most frequent cause of “excess death” during the winter months in 
elderly and high-risk adults, with a disease burden similar to that of influenza.94 Though 
expensive, the only FDA-approved therapy, palivizumab, is effective when administered 
prophylactically.205 Given the frequency and potential severity of RSV infection, as well 
as the current lack of a vaccine or cost-effective therapies, the development of novel 
preventative and therapeutic measures is imperative.  
RSV infection activates multiple arms of the immune response, resulting in 
severe and prolonged lung inflammation. By infecting the respiratory epithelium, RSV 
upregulates type I interferons. Both Th1 and natural killer (NK) cells produce interferon-
γ (IFN-γ), which potentiates the polarization of incoming T cells to an antiviral, cytolytic 
type 1 response which is required for viral clearance.97,98 However, pathogenic viral 
mediators can dysregulate host immune responses during infection. For example, RSV 
NS1 and NS2 proteins suppress type I interferons,100 and RSV G protein promotes 
inappropriate inflammatory responses via CX3C chemokine mimicry.101 Reduced viral 
control by defective host immunity and over activation of the type 2 host response lead 
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to severe RSV infection. The type 2 response mediates airway mucus production, which 
directly contributes to airway obstruction and respiratory failure.102 Group 2 innate 
lymphoid cells (ILC2), CD4+ Th2 cells, and basophils produce type 2 cytokines, which 
mediate airway responsiveness and mucus production during severe infection.108,206–209 
The epithelial-associated cytokine IL-33 activates cells that produce type 2 cytokines 
including ILC2, Th2 cells, and basophils to secrete IL-13, and polarizes naïve CD4+ T 
cells to differentiate into type 2 cytokine-producing effector Th2 cells.28 As a central 
mediator of both innate and adaptive immunity-regulated lung inflammation, IL-33 has 
been identified as an important therapeutic target in inhibiting airway disease.29 
Glucagon-like peptide-1 (GLP-1) is an emerging anti-inflammatory therapeutic 
target. GLP-1 is a peptide hormone that is synthesized and released by 
enteroendocrine L cells in the ileum and large intestine following oral food intake.162,165 
As GLP-1 induces insulin and inhibits glucagon secretion in a glucose-dependent 
fashion,169 GLP-1R agonists are approved by the Food and Drug Administration (FDA) 
for the treatment of Type II diabetes (T2D).170 Importantly, GLP-1R signaling does not 
stimulate insulin secretion or decrease glucose levels in people without diabetes under 
euglycemic conditions, carries little risk for hypoglycemic events, and is administered at 
doses that do not produce weight loss.210 Recent reports demonstrate that GLP-1R 
signaling attenuates inflammation during cardiovascular disease, psoriasis, and chronic 
lung disease such as allergic airway inflammation and bleomycin-induced fibrosis.181,182 
However, no studies have investigated the effect of GLP-1R signaling during viral-
associated immunopathology. 
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We found that GLP-1R agonist treatment decreased airway inflammation, airway 
responsiveness, and airway mucus production in mice infected with a strain of RSV that 
was isolated from a hospitalized infant with severe lower respiratory tract infection and 
bronchiolitis. GLP-1R agonist treatment decreased lung IL-13 and IL-33 levels, with 
concurrent decreases in IL-13+ group 2 innate lymphoid cells (ILC2), CD4+ Th2 cells, 
and basophils, as well as IL-33+ epithelial cells. Moreover, the GLP-1R agonist 
prevented airway inflammation and did not impact viral load, anti-viral interferon and 
antibody production during secondary RSV infection. Relative to the respective mock-
infected groups, RSV-infected GLP-1R agonist-treated mice did not have increased 
weight loss compared to vehicle treated mice. Lastly, a phenome-wide association 
study (PheWAS) identified a link between GLP-1R signaling and acute bronchitis and 
bronchiolitis in humans. This report is the first to identify an FDA-approved 
pharmacologic agent that inhibits lung IL-33 release and demonstrate that GLP-1R 
signaling may be a novel treatment strategy for RSV bronchiolitis. 
 
Materials and Methods 
Virus and Mice 
RSV strain 12/12-6 was isolated in 2012 from a hospitalized infant with severe 
lower respiratory tract infection and bronchiolitis as part of the INSPIRE study.211 RSV 
was propagated and titrated in HEp-2 cells as previously described.212 Mock inoculum 
was prepared by collecting cell culture supernatant from lysed, uninfected HEp-2 cells. 
8 week old female BALB/cJ mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). Il33Citrine/+ reporter mice were generated by crossbreeding WT BALB/c 
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mice and Il33Citrine/Citrine mice that were the kind gift of Dr. Andrew N.J. McKenzie.213 Mice 
were maintained under specific pathogen free conditions and used in compliance with 
the revised 2011 Guide for the Care and Use of Laboratory Animals prepared by the 
Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal 
Resources, National Research Council.214 For infection, mice were anesthetized by 
intraperitoneal injection of ketamine/xylazine solution and inoculated via intranasal 
delivery with 9 x 105 PFU of RSV 12/12-6 or an equal volume of mock inoculum as 
previously described.215 Weight loss was measured daily. The GLP-1R agonist 
liraglutide (Novo Nordisk, Plainsboro, NJ) was initiated at the same dose that is used in 
patients with Type II Diabetes. This was increased in two-fold increments daily until the 
final dose of 0.2 mg/kg weight was reached. The vehicle for liraglutide, 0.1% BSA in 
PBS, was used as a control. Treatment was given subcutaneously beginning 2 days 
prior to infection or beginning on the same day as infection and given twice daily until 
the mice were euthanized.  
 
BAL and PAS Staining 
0.8 mL saline was instilled through a tracheostomy tube and withdrawn via 
syringe to obtain BAL fluid. Total cells were counted on a hemocytometer by using 
trypan blue exclusion. For cell differentials, 0.1 mL of BAL fluid was prepared via 
cytospin (Thermo Fisher Scientific, Waltham, MA) and subsequently fixed and stained 
using DiffQuik (American Scientific Products, Columbus, OH). Differential counts were 
based on counts of 200 cells, using standard morphological criteria to visualize 
neutrophils, eosinophils, lymphocytes, or macrophages. For PAS staining, lungs were 
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perfused with PBS, inflated with 10% neutral buffered formalin, and fixed in 10% neutral 
buffered formalin for 24 hours at room temperature. Lungs were then paraffin 
embedded, sectioned (5 μm), and stained with periodic acid-Schiff (PAS) to visualize 
mucus. Small and medium sized airways were scored for mucus by a trained 
pathologist blinded to the experimental information using the following scoring scheme: 
(0) no PAS positive cells observed in cross sections of medium to small airways; (1) 
less than 10 PAS positive cells observed in cross sections of medium to small airways; 
(2) greater than 10 PAS positive cells observed in cross sections of medium to small 
airways; or (3) greater than 10 PAS positive cells observed in cross sections of medium 
to small airways with mucous strands observed in air spaces. 
 
Airway Responsiveness 
Airway responsiveness was measured as previously described.216,217 Briefly, 
mice were anesthetized with an intraperitoneal injection of pentobarbital sodium (85 
mg/kg). A tracheostomy tube was inserted for ventilation. The internal jugular vein was 
cannulated for intravenous delivery of acetyl-β-methacholine. The mice were then 
placed in a whole body plethysmography chamber and mechanically ventilated. 
Precision glass microsyringes were used to deliver increasing doses of acetyl-β-
methacholine. Baseline airway resistance measurements were collected followed by 
measurements with 137, 411, 1233, and 3700 μg/kg body weight of acetyl-β-
methacholine (Sigma-Aldrich, Saint Louis, MO). Peak airway resistance measurements 
for each dose were recorded.   
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ELISA 
Lungs were snap-frozen in liquid nitrogen at the time of harvest. Lungs were 
mechanically disrupted using 1 mL of MEM media and homogenized via BeadBeater 
(BioSpec Products, Bartlesville, OK). Protein measurements were performed using 
either Duoset (IL-33), Quantikine (IL-13, IFN-γ, and IL-27), or Verikine (IFN-α and IFN-
β) enzyme-linked immunosorbent assay (ELISA) kits according to manufacturer 
instructions (R&D Systems, Minneapolis, MN). Serum RSV F-protein-specific antibody 
was measured as previously described.212  
 
Flow Cytometry 
Lungs were harvested, minced, and digested in RPMI media with 5% FBS, 1 
mg/mL collagenase, and 0.02 mg/mL DNase I for 40 minutes at 37°C. The digestion 
was stopped with 100 µl of 0.5 M EDTA, and a single cell suspension was generated by 
straining these digestions through a 70 μm filter. RBC lysis (BioLegend, San Diego, CA) 
was performed according to manufacturer instructions. Cells were stimulated in IMDM 
media with 10% FBS, 0.01 mM non-essential amino acids, penicillin/streptomycin, 1 mM 
sodium pyruvate, 10 ng/mL PMA, 1 μM ionomycin, and 0.07% monensin for 4 hours at 
37°C. Cells were stained with Live/Dead Blue (Life Technologies, Carlsbad, CA) and 
combinations of the following surface markers: CD45 (30-F11), CD25 (PC61.5), FcεR1 
(MAR-1), DX5 (DX5), FcεR1 (MAR-1), and NKG2D (CX5) from eBioscience (San Diego, 
CA); CD127 (SB/199), CD3 (17A2), CD146 (ME-9F1), and EpCAM (G8.8) from 
BioLegend (San Diego, CA); CD4 (H129.19) from BD Biosciences (San Jose, CA); and/ 
or a surface marker cocktail containing CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7-
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4, and Ter-119 from Miltenyi (Bergisch Gladbach, Germany). Cells were fixed/ 
permeabolized for 12 hours in Cytofix/ Cytoperm (BD Biosciences) and stained with 
combinations of the following intracellular markers: IL-13 (eBio13A) and IFN-γ (XMG1.2) 
from eBioscience. Anti-FcR antibody (BD Biosciences) was used to prevent nonspecific 
staining. All samples were run on a BD LSR II Flow Cytometer and analyzed using 
FlowJo (Version 10; Treestar, Ashland, OR). ILC were defined as Lineage- CD45+ 
CD25+ CD127+ cells where Lineage (Lin) includes (CD3, CD5, CD45R [B220], CD11b, 
Gr-1 [Ly-6G/C], 7-4, and Ter-119). ILC2 were defined as ILC that expressed IL-13. Th 
cells were defined as CD3+ CD4+ cells, basophils were defined as DX5+ FcεR1+ cells, 
NK cells were defined as CD3- DX5+ cells, and epithelial cells were defined as CD45- 
CD146+ EpCAM+ cells.  MFI was determined as the geometric mean. 
 
Viral Load 
Lungs were snap-frozen in liquid nitrogen at the time of harvest. Thawed lungs 
were resuspended in 1 mL of sterile MEM media or TRIzol reagent (Invitrogen, 
Carlsbad, CA) and homogenized via BeadBeater (BioSpec Products). Total RNA was 
isolated using TRIzol reagent and cDNA was generated for qPCR analysis of RSV-M 
and GAPDH. Commercially available primers and probes for GAPDH were used 
(Applied Biosystems, Foster City, CA). Custom primers were designed to measure 
RSV-M 218. Gene expression was normalized to GAPDH before the fold change was 
calculated. The fold change in gene expression was calculated via the comparison of 
gene expression to that of lungs from RSV-infected, vehicle-treated mice. 
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Antibody ELISA 
Ectodomain F protein from RSV A2 was fused to a GCN4 trimerization domain 
and a His tag and expressed in mammalian cells, as previously described. 219 Immulon 
2B (Thermo Scientific, Rochester, NY) plates were coated with 150 ng of RSV F protein 
in PBS overnight at 4°C. Plates were blocked with 1% BSA in PBS for 1 hour at room 
temperature. Supernatants were serially diluted 1:2 starting at 1:80 over 6 total dilutions, 
and plates were incubated for 1 hour at room temperature. RSV-specific antibody was 
detected using horseradish peroxidase-conjugated goat anti-mouse antibody specific for 
mouse IgG (1:5,000), IgG1 (1:500), or IgG2a (1:500) for 1 hour at room temperature 
(Southern Biotech, Birmingham, AL). Plates were developed in Ultra-TMB (Pierce, 
Rockford, IL) and the reaction was stopped with 1M HCl. Absorbance values (450 nm) 
were measured and assessed using Gen 5 software (BioTk, Vinooski, VT). The serum 
endpoint dilution at 0.2 absorbance units above background (PBS blank) was calculated 
for each antibody type. 
 
Statistical Analysis 
Groups were compared using unpaired t-test, one-way analysis of variance 
(ANOVA) with Bonferroni post test, or two-way ANOVA with Dunn’s multiple comparison 
test, as appropriate with GraphPad Prism (Version 5; GraphPad Software, San Diego, 
CA). Measurements below the limit of detection were assigned half of the value of the 
limit of detection for statistical comparisons. 
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PheWAS Study 
The rs7578597 variant of THADA, a loss-of-function single polymorphism 
nucleotide (SNP) encoding thyroid adenoma-associated protein, associated with lower 
beta-cell response to GLP-1.220 To investigate associations with THADA, we used a 
population of 29,713 individuals (age >18 years) of European ancestry with genotyping 
on Illumina HumanExome BeadChip version 1.1 and available electronic health record 
(EHR) data from the Vanderbilt BioVU DNA biobank.221 This platform contained the 
THADA SNP rs7578597, which corresponds to a threonine to alanine in multiple splice 
variants. The minor T allele of rs7578597 was present in 11% of individuals. We then 
evaluated all phenotypes defined using a PheWAS of this SNP using previously 
described methods.222 Briefly, the method defines cases for 1,000 phenotypes by the 
presence of specific International Classification of Diseases, Ninth Revision (ICD9), 
codes on at least two different days. Controls for each phenotype are defined as 
individuals who lack case ICD9 codes and other codes that are related. For example, 
cases of the “acute bronchitis and bronchiolitis” phenotype are defined with the ICD9 
code 483, while its controls are defined as absence of the 483 ICD9 codes. We used 
version 1.2 of the PheWAS code terminology system and the R PheWAS package to 
calculate the PheWAS and graph results,223 both of which can be downloaded from 
http://phewascatalog.org. We used logistic regression for each phenotype with 40 cases 
or more, adjusted for age and sex, assuming an additive genetic model. 
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Results 
GLP-1R signaling attenuates RSV-induced airway inflammation, airway 
responsiveness, and airway mucus 
We first evaluated whether the lungs of mice infected with RSV 12/12-6, a clinical 
isolate strain that was isolated from a hospitalized infant with severe lower respiratory 
tract infection and bronchiolitis, exhibited features of type 2-mediated immunopathology. 
Eight week old mice were infected with 9 x 105 PFU of RSV and lungs were harvested 
on days 6 or 8 for ELISA or PAS staining of histologic sections. RSV 12/12-6 induced 
significant lung IL-13 and airway mucus production, mimicking what is seen in patients 
with severe infection (Figure 3.1).  
We hypothesized that GLP-1R signaling attenuates RSV-induced 
immunopathology. To test this hypothesis, GLP-1R agonist or vehicle was administered 
subcutaneously beginning 2 days prior to RSV infection and given twice daily until all 
endpoints (Figure 3.2).  To assess the physiological effect of GLP-1R agonist treatment 
on cellular inflammation, we assessed BAL cell counts and differentials on day 6. RSV 
infection significantly increased the number of total BAL cells compared to mock-
infected mice. GLP-1R agonist treatment significantly decreased the number of RSV-
induced total BAL cells and lymphocytes compared to vehicle treatment (Figure 3.3A). 
We next sought to determine the effect of GLP-1R signaling on airway obstruction and 
responsiveness which are physiological mediators of respiratory failure during severe 
infection. To allow time for IL-13 to induce physiologic changes in the airways, we 
performed methacholine challenge at day 8 post-infection. There was a significant 
decrease in airway responsiveness in the RSV-infected GLP-1R agonist-treated group   
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Figure 3.1. RSV 12/12-6 induces lung IL-13 and mucus production. BALB/cJ mice 
were infected with 9 x 105 PFU of RSV strain 12/12-6 and lungs were harvested for 
ELISA or histopathology. ELISA for (A) IL-13 and (B) IFN-γ in the whole lung 
homogenate (both lungs) 6 days after infection. (C) Representative PAS-stained section 
of mucus-containing airway in the lungs 8 days after infection. Data plotted as mean + 
SEM. n = 5 mice per group. ***p < 0.001 by one-way ANOVA. Dashed line is the limit of 
detection of the assay. 
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Figure 3.2. Protocol for in vivo administration of GLP-1R agonist or vehicle and 
subsequent infection with RSV or mock preparation. BALB/cJ mice were infected 
with 9 x 105 PFU of RSV strain 12/12-6 or mock inoculum on day -2. On day 0, the 
GLP-1R agonist liraglutide or vehicle (0.1% BSA in PBS) was initiated. Treatment was 
given twice daily until the mice were euthanized. 
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Figure 3.3. GLP-1R agonist decreases RSV-induced airway inflammation, airway 
responsiveness, and airway mucus accumulation. BALB/cJ mice were treated with 
GLP-1R agonist or vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock 
inoculum. (A) BAL cell counts 6 days post-infection. (B) Airway responsiveness 
measured at baseline and increasing doses of methacholine 8 days post-infection. (C) 
Representative PAS-stained section of mucus-containing airway in the lungs 8 days 
post-infection (40x magnification); arrowhead denotes intraluminal mucus strand. (D) 
Quantification of airway mucus from the experiment in C. Data plotted as mean + SEM. 
n = 3-6 mice per group representative of 3 (A) or 2 (C&D) independent experiments. n = 
6-12 mice per group combined from 2 independent experiments (B). *p < 0.05, **p < 
0.01, ***p < 0.001 by two-way (A-B) or one-way (D) ANOVA. BL = baseline.  
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compared to RSV-infected vehicle-treated mice with increasing methacholine 
concentration (Figure 3.3B). No significant differences in airway responsiveness were 
observed between mock-infected GLP-1R agonist and vehicle-treated mice. To 
determine the effect of GLP-1R signaling on mucous cell metaplasia and airway mucus 
accumulation, we evaluated histologic sections of lungs stained with PAS to detect 
mucus at day 8 post-infection. In mock-infected mice, there was minimal or absent 
mucous cell metaplasia (Figure 3.3C). In RSV-infected vehicle-treated mice, there was 
appreciable mucous cell metaplasia and airway mucus accumulation with intraluminal 
mucus strands. RSV-infected GLP-1R agonist-treated mice also demonstrated some 
mucous cell metaplasia but they had no substantial intraluminal mucus accumulation. 
Collective scoring of airways from multiple mice showed a significant decrease in mucus 
severity score in RSV-infected GLP-1R agonist-treated mice compared to RSV-infected 
vehicle-treated mice (Figure 3.3D). Collectively, these data show that GLP-1R signaling 
attenuates RSV-induced immunopathology. 
 
GLP-1R signaling decreases the concentration of IL-13 and the numbers of IL-13-
producing ILC2, Th2 cells, and basophils in the lungs 
Our finding that GLP-1R agonist treatment significantly attenuated RSV-induced 
immunopathology led us to hypothesize that GLP-1R signaling suppresses RSV-
induced type 2 responses. To determine the effect of GLP-1R on type 2 cytokine 
production, we evaluated lung IL-13 expression 6 days post-infection, at the height of 
lung IL-13 during RSV infection. RSV infection significantly increased lung IL-13 
production compared to mock-infected mice (Figure 3.4A). RSV-infected GLP-1R   
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Figure 3.4. GLP-1R agonist decreases whole lung IL-13 accumulation and IL-13-
producing ILC2 6 days after RSV infection. BALB/cJ mice were treated with GLP-1R 
agonist or vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock 
inoculum. (A) ELISA for IL-13 in whole lung homogenate (right lung only). (B) Total 
number of live lung cells, (C) total number of IL-13+ ILC2, and (D) percent of ILC that 
are IL-13+. MFI of (E) IL-13 and (F) CD127 staining in ILC2. (G) Representative IL-13 
expression measured by flow cytometry in ILC2. Data plotted as mean + SEM. n = 3-6 
mice per group representative of 3 (A) or 2 (B-F) independent experiments. *p < 0.05, 
**p < 0.01, ***p < 0.001 by one-way ANOVA. 
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agonist-treated mice had significantly decreased levels of lung IL-13 compared to RSV- 
infected vehicle-treated mice. Administration of GLP-1R agonist beginning on the same 
day of RSV infection also decreased lung IL-13 and airway mucus production (Figure 
3.5). We next sought to identify the cellular sources of IL-13 that GLP-1R signaling was 
inhibiting. ILC2 have recently been identified as important producers of IL-13 during 
RSV infection.207,208 No single surface marker(s) is presently known to identify ILC2 
exclusively. We identified innate lymphocytes (ILC) by flow cytometry as hematopoietic 
lineage marker (CD3, CD5, B220, CD11b, Gr-1, 7-4, and Ter-119) negative CD45+ 
CD25+ CD127+ and ILC2 as ILC that are IL-13+ (Figure 3.6A).224 There were significant 
increases in the total number of cells in the lung, the total number of ILC2, and the 
percentage of ILC that were IL-13+ in the RSV-infected group compared to the mock-
infected group at day 6 post-infection (Figure 3.4B-D). GLP-1R agonist treatment in 
RSV-infected mice significantly decreased the total number of cells in the lung, the total 
number of ILC2, and the percentage of ILC that were IL-13+ compared to RSV-infected 
vehicle-treated mice (Figure 3.4G). There was significantly decreased MFI of IL-13 and 
CD127 in the ILC2 of RSV-infected GLP-1R agonist-treated mice compared to RSV-
infected vehicle-treated mice, indicating decreased IL-13 production and CD127 
expression on a per ILC2 basis with GLP-1R agonist treatment (Figure 3.4E-F & Figure 
3.7). These data demonstrate that GLP-1R signaling inhibits type 2 immune responses, 
and specifically IL-13-producing ILC2, during RSV infection. 
Next we enumerated the number of total CD4+ T cells and basophils to determine 
the effect of GLP-1R signaling on the other major cellular sources of IL-13 during RSV 
infection. The gating strategy for IL-13+ Th2 cells and basophils are shown in Figure   
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Figure 3.5. GLP-1R agonist decreases RSV-induced whole lung IL-13 
accumulation and airway mucus production. BALB/cJ mice were treated with GLP-
1R agonist or vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock 
inoculum. (A) Protocol for in vivo administration of GLP-1R agonist or vehicle and 
simultaneous infection with RSV or mock preparation. (B) ELISA for IL-13 in whole lung 
homogenate 6 days after infection. (C) Quantification of airway mucus in the lungs 8 
days post-infection. Data plotted as mean + SEM. n = 5 mice per group. *p < 0.05 by 
unpaired t-test. 
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Figure 3.6. Flow gating for ILC, CD4+ T cells, NK cells, basophils, and epithelial 
cells. (A) ILC were defined as viable Lin- CD45+ CD25+ CD127+ cells. (B) CD4+ T cells 
were defined as viable CD3+ CD4+ cells. (C) Basophils were defined as viable FcεRI+ 
DX5+ cells. (D) NK cells were defined as viable DX5+ CD3- cells. (E) Epithelial cells 
were defined as viable CD45- CD146+ EpCAM+ cells. 
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Figure 3.7. GLP-1R agonist decreases MFI of IL-13 and CD127 staining in ILC2 6 
days after RSV infection. BALB/cJ mice were treated with GLP-1R agonist or vehicle 
and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock inoculum. Representative 
MFI of (A) IL-13 and (B) CD127 staining in ILC2 by flow cytometry. 
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3.6B and C. CD4+ T cells were defined as CD3+ CD4+ cells, and basophils were defined 
as DX5+ FcεR1+ cells. The total numbers of CD4+ T cells and basophils as well as IL-
13+Th2 cells and basophils were significantly increased in RSV-infected mice compared 
to mock-infected mice (Figure 3.8). GLP-1R agonist treatment in RSV-infected mice 
significantly decreased the numbers of CD4+ cells and basophils as well as IL-13+ Th2 
cells and basophils compared to RSV-infected vehicle-treated mice (Figure 3.8). 
Together, these data indicate that inhibition of IL-13-producing ILC2, Th2 cells, and 
basophils collectively contribute to the decrease in total lung IL-13 seen with GLP-1R 
agonist treatment. 
 
GLP-1R signaling inhibits the production of IL-33 and the number of IL-33-producing 
epithelial cells in the lungs 
IL-33 activates type 2 cytokine-producing immune cells including ILC2, Th2, and 
basophils. To determine whether GLP-1R agonist treatment mediates IL-33 production 
during RSV infection, we measured the whole lung concentration of IL-33 protein 12 
hours post-infection, at the height of lung IL-33 during RSV infection.207 RSV infection 
significantly increased the total concentration of IL-33 in the lungs compared to mock-
infected mice (Figure 3.9A). RSV-infected GLP-1R agonist-treated mice had 
significantly decreased levels of lung IL-33 compared to RSV-infected vehicle-treated 
mice. To examine the effect of GLP-1R signaling on IL-33 expression on a per epithelial 
cell basis, we used Il33Citrine/+ reporter mice. Epithelial cells were defined as CD45- 
CD146+ EpCAM+ cells (Figure 3.6E). There were significant increases in the total 
number of cells in the lung and the percentage of epithelial cells that were IL-33+ in the   
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Figure 3.8. GLP-1R agonist decreases IL-13-producing Th2 cells and basophils 6 
days after RSV infection. BALB/cJ mice were treated with GLP-1R agonist or vehicle 
and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock inoculum. (A) Total 
number of CD4+ Th2 cells, (B) IL-13+ Th2 cells, (C) basophils, and (D) IL-13+ basophils. 
Data plotted as mean + SEM. n = 3-6 mice per group representative of 2 independent 
experiments. **p < 0.01, ***p < 0.001 by one-way ANOVA. 
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Figure 3.9. GLP-1R agonist decreases whole lung IL-33 accumulation and IL-33-
producing epithelial cells 12 hours after RSV infection. Il33Citrine/+ reporter mice were 
treated with GLP-1R agonist or vehicle and infected with 9 x 105 PFU of RSV strain 
12/12-6 or mock inoculum. (A) ELISA for IL-33 in whole lung homogenate (left lung 
only). (B) Total number of live lung cells, (C) total number of IL-33+ epithelial cells, and 
(D) percent of epithelial cells that are IL-33+. MFI of (E) IL-33 expression in epithelial 
cells. (F) Representative IL-33 expression measured by flow cytometry in epithelial 
cells. Data plotted as mean + SEM. n = 3-6 mice per group representative of 2 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA. 
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RSV-infected group compared to the mock-infected group at day 6 post-infection  
(Figure 3.9B-D). GLP-1R agonist treatment in RSV-infected mice significantly 
decreased the total number of cells in the lung, the total number of IL-33-producing 
epithelial cells, and the percentage of epithelial cells that were IL-33+ compared to RSV-
infected vehicle-treated mice. There was significantly decreased MFI of IL-33 in the 
epithelial cells of GLP-1R agonist-treated mice compared to vehicle-treated mice, 
indicating decreased IL-33 production on a per epithelial cell basis with GLP-1R agonist 
treatment (Figure 3.9E-F). These data indicate that GLP-1R agonist treatment inhibits 
IL-33-producing epithelial cells during RSV infection. 
 
GLP-1R signaling does not impact weight loss, viral load, or anti-viral interferon 
responses during RSV infection 
We next sought to determine the effect of GLP-1R signaling on anti-viral 
responses during RSV infection. To determine whether GLP-1R agonist treatment had a 
deleterious effect on viral-associated disease severity parameters, we evaluated weight 
loss after infection. Relative to the respective mock-infected groups, RSV-infected GLP-
1R agonist-treated mice did not have increased weight loss compared to vehicle-treated 
mice (Figure 3.10A). Next, we sought to determine whether GLP-1R agonist treatment 
altered viral load, an indicator of RSV disease severity.225 There were no significant 
differences in the viral load at days 4 or 6 after RSV infection between RSV-infected 
GLP-1R agonist and vehicle-treated mice (Figure 3.10B). Consistent with these data, 
we did not observe any significant differences in lung IFN-γ expression or IFN-γ+ Th1 
and NK cells between RSV-infected GLP-1R agonist and vehicle-treated mice 6 days 
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post-infection (Figure 3.10C-E). The gating strategy for IFN-γ+ Th1 and NK cells are 
shown in Figure 3.6B and D. NK cells were defined as CD3- DX5+ cells. Further, there 
were no significant differences in lung IFN-α, IFN-β, or IL-27 production 12 hours post-
infection (Figure 3.11). 
 
GLP-1R signaling prevents airway inflammation and does not impact RSV F-protein 
specific antibody responses during secondary RSV infection 
To determine whether GLP-1R agonist treatment during primary infection has an 
impact on the immune response to a later secondary infection, we infected mice with 
RSV a second time 30 days following primary RSV infection (Figure 3.12). The mice 
were assessed 6 days after secondary RSV infection. GLP-1R analog treatment during 
primary infection significantly decreased the number of RSV-induced total BAL cells and 
lymphocytes compared to vehicle treatment after secondary infection (Figure 3.13A). 
The mice treated with GLP-1R agonist during primary infection did not exhibit altered 
lung IFN-γ expression compared to vehicle-treated mice during secondary RSV 
infection (Figure 3.13B). This was consistent with the unaltered lung IFN-γ production 
between GLP-1R agonist and vehicle-treated mice during primary RSV infection 
(Figure 3.10C). GLP-1R agonist treatment during primary infection did not alter RSV F-
protein-specific antibody responses following secondary infection (Figure 3.13C-E). 
This was consistent with the unaltered viral load between RSV-infected GLP-1R agonist 
and vehicle-treated mice (Figure 3.10B). Collectively, these data demonstrate that 
GLP-1R agonist treatment does not exacerbate disease or impede anti-viral responses,  
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Figure 3.10. GLP-1R agonist does not have negative effects on weight loss, viral 
load, or IFN-γ production 6 days after RSV infection. BALB/cJ mice were treated 
with GLP-1R agonist or vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or 
mock inoculum. (A) Percent of original body weight. (B) Lung mRNA levels for RSV M 
protein were determined on days 4 and 6 after infection and normalized to GAPDH. (C) 
ELISA for IFN-γ in whole lung homogenate (right lung only). (D) Total number of IFN-γ+ 
Th1 and (E) IFN-γ+ NK cells 6 days after infection. Data plotted as mean + SEM. n = 3-6 
mice per group representative of 2 (A, C-E) or 3 (B) independent experiments. *p < 0.05 
and **p < 0.01 by two-way ANOVA. NS = not significant. 
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Figure 3.11. GLP-1R agonist does not have negative effects on early interferon 
responses during RSV infection. BALB/cJ mice were treated with GLP-1R agonist or 
vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock inoculum. ELISAs 
for (A) IFN-α, (B) IFN-β, and (C) IL-27 in whole lung homogenate. Data plotted as mean 
+ SEM. n = 3-6 mice per group representative of 3 experiments. Two-way ANOVA.  
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Figure 3.12. Protocol for administration of GLP-1R agonist or vehicle, primary 
RSV or mock infection, and subsequent secondary RSV or mock infection. 
BALB/cJ mice were treated with GLP-1R agonist or vehicle beginning on day -2 and 
infected with 9 x 105 PFU of RSV strain 12/12-6 or mock inoculum on day 0. Treatment 
was given twice daily until day 8. On day 30, mice were infected a second time with 9 x 
105 PFU of RSV strain 12/12-6 or mock inoculum. 
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Figure 3.13. GLP-1R agonist treatment during primary infection prevents airway 
inflammation and does not have negative effects on antibody responses or IFN-γ 
production during secondary RSV infection. BALB/cJ mice were treated with GLP-
1R agonist or vehicle and infected with 9 x 105 PFU of RSV strain 12/12-6 or mock 
inoculum. Mice were re-infected 30 days after primary infection, and serum was 
collected 6 days after secondary infection. (A) BAL cell counts 6 days post-infection. (B) 
ELISA for IFN-γ in whole lung homogenate (right lung only). ELISA for RSV F-protein-
specific (C) IgG, (D) IgG1, and (E) IgG2a. Data plotted as mean + SEM. n = 6-12 mice 
per group combined from 2 independent experiments. One-way ANOVA. NS = not 
significant. 
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and implicate GLP-1R agonist as a potential therapeutic for attenuating type 2- 
associated immunopathology during RSV infection. 
 
Human PheWAS analysis identifies an association between GLP-1 signaling and acute 
bronchitis and bronchiolitis 
 Based on the GLP-1R signaling-mediated attenuation of type 2-associated 
immunopathology during RSV infection, we next sought to identify associations between 
GLP-1R and human RSV disease. The rs7578597 variant of THADA, a loss-of-function 
single polymorphism nucleotide (SNP) encoding thyroid adenoma-associated protein, 
associated with lower beta-cell response to GLP-1.220 We performed a phenome-wide 
association study on the THADA SNP rs7578597 (missense, T1187A) and 1,000 
phenotypes in 29,713 individuals of European ancestry (EA) from the Vanderbilt BioVU 
biobank following previously validated methods.226 The previously reported association 
with diabetes mellitus was confirmed (odds ratio [OR] = 0.88, P = 1.4 x 10-3; Table 3.1). 
A highly significant association of rs7578597 with acute bronchitis and bronchiolitis was 
identified (OR = 1.24, P = 6.3 x 10-3; Figure 3.14 and Table 3.1). There were 1,223 
acute bronchitis and bronchiolitis cases and 22,347 controls. Interestingly, rs7578597 
also significantly associated with two other respiratory phenotypes: acute pharyngitis 
(OR = 1.31 P = 5.1 x 10-3) and postinflammatory pulmonary fibrosis (OR = 1.43, P = 9.4 
x 10-3; Table 3.1).  
 85 
 
Figure 3.14. Phenome-wide association study (PheWAS) plot for THADA 
rs7578597 shows significant association between THADA and acute bronchitis 
and bronchiolitis in humans. Each panel represents 1,000 phenotypes tested for 
association with THADA rs7578597, using logistic regression assuming an additive 
genetic model adjusted for age, sex, study site, and the first 3 principal components. 
Phenotypes were grouped along the x axis by categorization within the PheWAS code 
hierarchy. rs7578597 associated with acute bronchitis and bronchiolitis associated (OR 
= 1.24, P = 6.3 x 10-3). 
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Table 3.1. PheWAS results for THADA rs7578597 in humans. All phenotypes with 
p<0.01 are reported below. 
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Discussion 
RSV infection is the leading cause of hospitalization in infants and an important 
cause of morbidity and mortality in elderly and high-risk adults. Moreover, severe RSV 
bronchiolitis is a significant risk factor for childhood asthma,87,227,228 and RSV infection is 
a major cause of asthma exacerbation in both children and adults.229 Current 
therapeutic options are limited. Ribavirin, a nucleoside analog that inhibits viral 
replication, demonstrated poor effectiveness in treating RSV-induced disease.230 
Corticosteroids are also ineffective during viral-induced bronchiolitis, failing to reduce 
the number of hospital admissions, length of stay, or disease severity.113,231,232 The 
majority of treatment strategies are thus supportive, focusing on fluid and respiratory 
maintenance. The only FDA-approved preventative therapy is palivizumab, an antibody 
directed against the surface-exposed RSV fusion protein, which given as prophylaxis 
decreases the number of RSV-associated hospitalizations by 55%.114,115 While effective, 
palivizumab is currently only recommended for infants in the first year of life with chronic 
lung disease, with hemodynamically significant congenital heart disease, or born 
significantly premature (< 29 weeks).233 Moreover, decades of research have failed to 
yield a safe and effective RSV vaccine. Recent reports indicate that FDA-approved 
GLP-1R agonists exhibit immunoregulatory properties, which has led to the first clinical 
trials studying their effect as anti-inflammatory compounds. Our study demonstrates for 
the first time that GLP-1R signaling is efficacious in inhibiting RSV-induced 
immunopathology, including IL-33 and IL-13 production as well as airway inflammation, 
responsiveness, and mucus production. 
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The effect of GLP-1R signaling on the function of cells that produce type 2 
cytokines during inflammation has not been described. Here we report that GLP-1R 
agonist treatment dramatically inhibited the function of ILC2. ILC2 are important 
producers of IL-13 and mediators of mucus production, and smooth muscle 
responsiveness during inflammatory disease states including viral and helminth 
infection, asthma, chronic rhinosinusitis, and atopic dermatitis.15–19,24,26,207,234–241 GLP-
1R signaling decreased the total number of ILC2 and the percentage of ILC that were 
IL-13+ during RSV infection. IL-7 signaling through CD127, the IL-7R, is required for ILC 
progenitors and ILC2 cells.241 GLP-1R signaling during RSV infection decreased CD127 
expression in ILC2, concurrent with a decreased IL-13 production on a per ILC2 basis. 
GLP-1R signaling also decreased the total numbers of IL-13-producing CD4+ Th2 cells 
and basophils. The concerted actions of innate and adaptive cellular mediators 
potentiate type 2-associated inflammation.23  ILC2 are critical for generating type 2 
inflammation because they recruit dendritic cells into the draining lymph node to 
promote Th2 cell differentiation locally in the airway wall.21 ILC2 also help establish the 
adaptive type 2 response by expressing MHC and costimulatory signals that trigger type 
2 cytokine production.22 CD4+Th2 cell and basophils concomitantly promote ILC2 
responses.22,23 Future studies will be required to precisely delineate the network of 
cellular interactions that modulate GLP-1 attenuation of RSV-induced IL-13 production. 
In this study, we show that GLP-1 collectively attenuates ILC2, Th2 cell, and basophil 
function during RSV infection. These findings are consistent with reports showing that 
the GLP-1R agonist liraglutide inhibits IL-4 production from activated invariant natural 
killer T (iNKT) cells in vitro, which was associated with reduced numbers of circulating 
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iNKT cells in patients with T2D.173 GLP-1R agonists also modulate the function of 
lymphocytes, neutrophils, and macrophages, decrease the production of cytokines and 
proinflammatory mediators, and inhibit the recruitment of hematopoietic cells.172–
174,176,242 The secondary messengers cAMP and PKA are associated with the anti-
inflammatory actions of GLP-1R agonists on thymocytes and macrophages.171,243 
Future studies will determine whether GLP-1R stimulation of these signaling molecules 
also mediate the inhibition of type 2 immune cells. 
IL-33 is a primary therapeutic target for inhibiting inflammatory lung disease 
given its central role in mediating both innate and adaptive immunity during lung 
inflammation.29 There have been no reports identifying pharmacologic agents approved 
for human use which also inhibit lung IL-33 production. Herein we show that GLP-1R 
signaling inhibited lung IL-33 production during RSV infection. IL-33 reduction 
represents one possible mechanism by which GLP-1R signaling inhibited type 2 
cytokine-producing cells. This is the first report of an FDA-approved pharmacologic 
agent inhibiting lung IL-33 production, and this finding has significant implications as it 
may provide an alternative to biologic therapies such as monoclonal antibodies or 
receptor antagonists that target IL-33-mediated diseases. 
Two recent trials of antiviral RSV therapies have shown early results of more 
rapid viral clearance and partial attenuation of disease severity.118,119 These promising 
results highlight the importance of developing anti-inflammatory therapies that can be 
used in conjunction with anti-virals to achieve complete disease abrogation. GLP-1R 
agonists are attractive anti-inflammatory therapeutic candidates, since we found that 
GLP-1R signaling does not have deleterious effects on protective antiviral responses 
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during infection. Our data demonstrate that GLP-1R signaling is unlikely to have 
negative effects on viral load or anti-viral interferon and antibody production. The lack of 
an effect by GLP-1R signaling on interferon production differs from what has been 
observed in other inflammatory diseases. The lack of an effect by GLP-1R signaling on 
interferon production differs from what has been observed in other inflammatory 
diseases. These data suggest that GLP-1R signaling may have unique effects on the 
type 1 response in different disease states. Determining the effect of GLP-1R signaling 
on distinct arms of the immune response in a given disease model is essential when 
developing therapeutics. Our results indicate that targeting the GLP-1 signaling axis is 
unlikely to exacerbate virally-associated disease metrics while still providing relief to 
type 2-associated immunopathology in the airways. 
A recent randomized control trial evaluated the effectiveness of liraglutide in 
reducing rates of first occurrence of death from cardiovascular disease, nonfatal 
myocardial infarction, or nonfatal stroke in patients with Type II diabetes presenting with 
a high risk for cardiovascular disease.178 This was associated with reduced rates of anti-
inflammatory effects independent of changes in insulin levels.177 A recent prospective 
cohort study evaluated the effectiveness of liraglutide in reducing disease severity in 
patients with psoriasis and Type II diabetes.180 Patients on liraglutide therapy had 
decreased Psoriasis Area and Severity Index (PASI) scores. GLP-1R signaling also 
decreased inflammatory cell infiltration and goblet cell hyperplasia in models of chronic 
lung inflammation such as allergic airway inflammation and bleomycin-induced 
fibrosis.181,182 Systemic and localized tissue inflammatory responses play a major role in 
the pathophysiology of cardiovascular disease, psoriasis, and chronic lung disease. 
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Given that dysregulated immune responses also drive severe RSV illness, it is intriguing 
to consider the therapeutic potential of GLP-1 for treating severe RSV infection. Our 
studies demonstrate that a GLP-1R agonist was capable of attenuating IL-33, IL-13, and 
type 2-associated immunopathology during primary RSV infection and preventing 
airway inflammation during secondary RSV infection, providing a small animal model 
proof of concept for this therapeutic approach. GLP-1R is expressed on human immune 
cells,173 supporting the translational significance of using GLP-1R to inhibit immune cells 
during RSV infection. Importantly, we administered liraglutide at the same dose that is 
used in patients with T2D. This dose does not stimulate insulin secretion or decrease 
glucose levels in people without diabetes under euglycemic conditions, carries little risk 
for hypoglycemic events, and is administered at doses that do not induce weight loss, 
an important safety consideration for use in infants and elderly patients.210 PheWAS is a 
new, validated reverse genetics approach that associates genetic variants of interest 
with phenotypes by linking a database of de-identified genotyping to a broad range of 
electronic medical record (EMR)-derived clinical phenotypes.222 The EMR phenotypes 
are derived from clusters of common International Classification of Diseases, Ninth 
Revision, codes. The loss-of-function THADA SNP rs7578597 associated with lower 
beta-cell response to GLP-1.220 Whether rs7578597 directly or indirectly affects GLP-1 
function remains to be determined. In this study, the identification of an association 
between a THADA sequence variant (rs7578597) and acute bronchitis and bronchiolitis 
in humans points to a potential role of GLP-1R signaling in RSV disease in humans. 
This study is the first investigation of GLP-1R signaling during viral infection. 
These data demonstrate the therapeutic potential of using GLP-1R agonist in a 
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therapeutically relevant manner (systemic administration) during RSV infection. We 
used the clinically relevant RSV strain 12/12-6, a virus that that was isolated from an 
infant with severe bronchiolitis and potentiated significant type 2 cytokine and mucus 
production in mice. We show that administration of a GLP-1R agonist attenuates type 2-
associated immunopathology during RSV infection. Together, these data highlight a 
novel potential therapeutic for RSV infection, a disease for which there currently is no 
treatment after infection has occurred. 
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CHAPTER IV 
 
PGI2 SIGNALING ORCHESTRATES REGULATORY AND EFFECTOR T CELL 
RESPONSES DURING ALLERGIC AIRWAY INFLAMMATION 
 
Introduction 
 Regulatory T cells (Tregs) are pivotal in suppressing immune responses and 
maintaining tolerance. Tregs are characterized by expression of the forkhead domain-
containing transcription factor Foxp3, the master regulator that is essential for Treg 
differentiation, function, and maintenance.47,244 Mutations in the Foxp3 locus result in 
Treg deficiency associated with the development of fatal multiorgan autoimmune 
diseases and allergies.245–247 Tregs constitute 5-10% of all CD4+ T cells. Natural Tregs 
(nTregs) differentiate in the thymus before their exit into the peripheral circulation. 
Inducible Tregs (iTregs) are generated following exposure to cognate antigen in the 
context of transforming growth factor (TGF)-β and interleukin (IL)-2. Following insult or 
challenge, activated Tregs accumulate and proliferate in local lymph nodes and tissues, 
subsequently inhibiting effector T cell (Teff) responses. nTregs and iTregs 
synergistically exert immunosuppressive activity via multiple mechanisms including cell-
cell contacts or secretion of immunomodulatory cytokines such as IL-10 and TGF-β. 
Since failure to maintain appropriate Treg numbers or function leads to autoimmune, 
malignant, and immunodeficient conditions, there is extensive interest in modulating 
Tregs as a therapeutic strategy for transplant, cancer, autoimmune disease, and 
allergy.248–250 
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Over the last four decades, the prevalence of allergic rhinitis, asthma, and atopic 
eczema increased markedly in developed countries.1,2 Mounting evidence suggests that 
drugs inhibiting cyclooxygenase (COX) enzymes in the arachidonic acid metabolic 
pathway may contribute to the increased allergy prevalence.251–253 Animal studies 
confirmed that COX inhibition increased allergic sensitization; augmented allergic 
airway inflammation; and enhanced lung expression of IL-4, IL-5, and IL-13 cytokines 
expressed by CD4+ Th2 cells, supporting a role for the COX pathway in regulating 
allergic inflammation.254–261 Because COX inhibition increases allergic inflammation in 
humans and experimental animal models, this suggests that a COX product restrains 
allergen-induced inflammatory responses and may be a novel treatment strategy for 
allergic diseases. 
Prostaglandin I2 (PGI2) is one of the lipid products formed in the COX pathway of 
arachidonic metabolism. The other lipid molecules produced in the COX pathway are 
prostaglandin E2 (PGE2), prostaglandin D2, prostaglandin F2α, and thromboxane A2. 
PGI2 binds to the G protein–coupled receptor IP and exerts its biological activities 
through autocrine and paracrine mechanisms. We have previously described the 
immune suppressive function of PGI2, and PGI2 analogs inhibited Th1 and Th2 effector 
cytokine production in vitro.154,196 Endothelial cell-derived PGI2 inhibited the recruitment 
of Th2 cells in the lung in an adoptive T-cell transfer model.262 In contrast, IP knockout 
(KO) mice have augmented Th2 immune responses, increased airway inflammation and 
hyper-responsiveness to OVA.156 Intranasal administration of the PGI2 analog iloprost 
protected against Th2-mediated cardinal features of asthma, including the development 
of allergic lung inflammation and methacholine-induced airway responsiveness (AR).159 
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Finally, absence of PGI2 signaling during sensitization broke immune tolerance elicited 
by prior mucosal allergen exposure.160 Therefore, PGI2 modulates immune responses 
and immune tolerance as well. 
We hypothesized that PGI2 signaling through IP protects against dysregulated 
Treg and Teff responses. Endogenous PGI2 signaling protected against autoimmune 
manifestations including splenomegaly and epicarditis that developed in aged IP KO 
mice. PGI2 promoted Treg stability and suppressive function as well as iTreg 
differentiation. PGI2 simultaneously promoted Teff proliferation and susceptibility to 
Treg- mediated suppression. There is extensive interest in the application of Tregs 
autoimmune and allergic diseases. Our findings demonstrate that PGI2 signaling 
promotes both Tregs and may represent a novel treatment strategy for Treg-mediated 
diseases. 
 
Materials and Methods 
Mice 
8 week old female WT BALB/c mice were purchased from Charles River 
Laboratories (Wilmington, MA). IP KO mice were generated by homologous 
recombination in embryonic stem cells and were backcrossed to a BALB/c background 
for 10 generations. Rag2-/-, Foxp3-GFP, DO11.10 TCR-transgenic mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME). Foxp3-GFP and DO11.10 mice were 
crossed with IP KO mice to produce Foxp3-GFP x IP KO and DO11.10 x IP KO mice. 
Age-matched mice were used at 8 to 12 or 36 to 40 (for aging experiments) weeks old. 
Mice were maintained under specific pathogen free conditions and used in compliance 
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with the revised 2011 Guide for the Care and Use of Laboratory Animals prepared by 
the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory 
Animal Resources, National Research Council.214 
 
Treg Suppression Assay 
CD4+ CD25– Teff and CD4+ CD25+ nTregs were isolated from WT or IP KO 
spleens by using a CD4+CD25+ Treg isolation kit (Miltenyi, San Diego, CA). Teff were 
labeled with 2.5 μM CFSE (Invitrogen) for 10 minutes at 37°C in PBS and 0.1% BSA 
and then co-cultured with an increasing ratio of Tregs in the presence of anti-CD3 
(1 μg/mL, 145-2C11; BD) and anti-CD28 (4 μg/mL, 37.51; BD). Cells were incubated for 
3 days and then harvested for flow cytometric analysis of CFSE dilution. Proliferation in 
Treg:Teff wells was compared to that in Teff only wells to determine the percent 
inhibition of proliferation at each ratio. The percent inhibition was calculated as follows: 
[(proliferation at ratio/ proliferation Teff only)*100]. 
 
iTreg Differentiation 
Naïve CD4+ T cells (1 × 105 cells/well) from the spleens of Foxp3-GFP or Foxp3-
GFP x IP KO mice were isolated using a CD4+CD62L+ T cell isolation kit (Miltenyi). T 
cells were activated with anti-CD3 (0.5 μg/mL) and differentiated into iTregs by adding 
rmIL-2 (0.25 μg/mL; Peprotech, Rocky Hill, NJ) and rhTGF-β (1 μg/mL; Peprotech). 
Cells were cultured for 6 days and then harvested for flow cytometric analysis of iTreg 
differentiation. 
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Flow Cytometry 
T cells were harvested and cells were blocked with anti-FcR antibody (BD 
Biosciences) and in select experiments stained with surface markers against CD3 
(17A2) from BioLegend (San Diego); CD4 (H129.19), or CD25 (PC61.5) from BD 
Biosciences (San Jose, CA). 
 
Cytokine Measurements 
Lungs were snap-frozen in liquid nitrogen at the time of harvest. Lungs were 
mechanically disrupted using 1 mL of MEM media and homogenized via BeadBeater 
(BioSpec Products, Bartlesville, OK). Protein measurements were performed using 
Quantikine (IL-13, and IL-5) enzyme-linked immunosorbent assay (ELISA) kits 
according to manufacturer instructions (R&D Systems, Minneapolis, MN). The levels of 
8 cytokines (IL-10, TGF-β, IFN-γ, IL-2, IL-4, IL-5, IL-13, and IL-17) in 25 uL of culture 
supernatant were assayed simultaneously, in duplicate, using a murine cytokine 8-plex 
antibody bead kit (EMD Millipore, Billerica, MA) and a Luminex-100 array assay reader 
(Luminex Corp., Austin, TX). 
 
OVA-Induced Airway Inflammation 
Naïve CD4+ Teff and CD4+CD25+ Tregs were isolated from DO11.10 spleens by 
using CD4+CD62L+ and CD4+CD25+ Treg isolation kits (Miltenyi). To facilitate homing of 
T cells to the lungs, Rag-2/- mice were challenged with OVA protein (50 μg in 50 μL of 
saline, intranasal (i.n.) or an equal volume of saline; Sigma-Aldrich, St. Louis, MO) on 
day −1. On day 0, 2.5 × 106 Teff from DO11.10 mice and 1, 0.5, or 2 × 106 Treg from 
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DO11.10 mice were adoptively transferred by retro-orbital injection. Mice were 
challenged with OVA for 3 consecutive days after cell transfer (50 μg/mouse/day, i.n.). 
Animals were sacrificed one day after the last airway challenge. 
 
RNA-Seq 
nTregs from the spleen of IP KO and WT mice were isolated with a FACSAria II 
(BD) for mRNA sequencing analysis. RNA from nTregs was isolated with a Total RNA 
Purification kit (Norgen, Thorold, ON). RNA was quantified with a Qubit 2.0 fluorometer 
(Invitrogen) and RNA quality was assessed on a Bioanalyzer 2100 (Agilent, Santa 
Clara, CA) with an RNA nano chip (Agilent). Samples with an RNA integrity number of 
>8 were used for library preparation. 50 ng of total RNA derived from splenic nTregs 
was used for low-input, stranded mRNA library preparation (NEB, Ipswich, MA). Library 
size distribution was assessed with a High Sensitivity DNA chip (Agilent) on a 
Bioanalyzer 2100. Paired-end 75-base pair sequencing, targeting at least 7 x 106 reads 
per sample, was performed on a HiSeq300 (Illumina) following the manufacturer’s 
protocol. Sequencing data were analyzed with GeneSpring (Version 13; Agilent). 
 
Quantitative PCR 
Total RNA was isolated using a Qiagen RNAesy micro kit (Valencia, CA) and 
cDNA was generated. Commercially available primers and probes for Pglyrp1, Ccdc61, 
and GAPDH were used (Applied Biosystems). Gene expression was normalized to 
GAPDH before the fold change was calculated. The fold change in gene expression 
was calculated via the comparison of gene expression to that of nTregs from WT mice. 
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Statistical Analysis 
Groups were compared using unpaired t-test, one-way analysis of variance 
(ANOVA) with Bonferroni post test, or two-way ANOVA with Dunn’s multiple comparison 
test, as appropriate with GraphPad Prism (Version 5; GraphPad Software, San Diego, 
CA). Measurements below the limit of detection were assigned half of the value of the 
limit of detection for statistical comparisons. 
 
Results 
IP deletion causes autoimmune manifestations and disrupts Treg homeostasis and 
stability 
We hypothesized that PGI2 signaling through IP protects against dysregulated 
Treg and Teff responses and subsequent autoimmune manifestations. Whole animal 
histopathology was performed on 36 week-old IP KO and WT mice. Aged IP KO mice 
exhibited splenomegaly and right ventricular free wall epicarditis (Figure 4.1A-C). 
HIstopathological evaluation of diseased mice showed infiltration in the spleen and 
heart, whereas WT mice did not show any noticeable pathology. 
To identify the underlying mechanisms responsible for the autoimmune 
manifestations observed in the aged IP KO mice, we first sought to examine whether T 
cell homeostasis and Treg stability were impaired in the periphery of IP KO mice. 
Comparison of IP KO mice with WT mice demonstrated unaltered spleen cellularity 
(Figure 4.1D). Flow cytometric analysis revealed increased numbers of CD3+ cells as 
well as CD3+CD4+ T cells in the spleens of IP KO mice compared to WT mice (Figure 
4.1E-G). The aforementioned difference in autoimmune manifestations between aged 
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IP KO mice and WT mice could be due to a numerical decrease in the Tregs in the 
absence of PGI2 signaling. While there was no significant difference in the proportion of 
CD4+ T cells that expressed CD25 and Foxp3 between IP KO and WT mice (Figure 
4.1H), the absolute number of Tregs was unexpectedly increased in IP KO mice 
compared to WT mice (Figure 4.1I). However, there was a statistically significant 2-fold 
decreased MFI of Foxp3 in the nTreg of IP KO mice compared to WT mice, indicating 
decreased Foxp3 protein expression on a per-Treg basis in IP KO mice (Figure 4.1J). 
There was no difference in CD25 MFI in Treg from IP KO and WT mice (Figure 4.1K). 
 
IP-deficient Treg are less suppressive and IP-deficient Teff are resistant to nTreg-
mediated suppression 
Despite the increased absolute number of Tregs, Teff numbers persisted in IP 
KO mice. This led us to hypothesize that a lack of endogenous PGI2 signaling results in 
general impairment of Treg suppressive function. To test this hypothesis, we isolated 
CD4+ CD25+ Treg and CD4+ CD25- Teff from IP KO and WT mice using commercially 
available magnetic sorting kits (Miltenyi, San Diego, CA) and performed in vitro 
suppression assays. Teff were labeled with CFSE and then co-cultured with an 
increasing ratio of Tregs in the presence of anti-CD3 and anti-CD28 for 3 days. 
Suppressive function was determined as the ability of Treg to suppress Teff 
proliferation. Tregs from IP KO mice were less suppressive compared to Tregs from WT 
mice (Figure 4.2A-C). We also evaluated production of the canonical Treg, Th1, Th2, 
and Th17 cytokines. Analysis of cytokine production showed decreased production of 
the immunoregulatory cytokine IL-10 as well as increased production of the Th2  
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Figure 4.1. IP deletion causes autoimmune manifestations and disrupts Treg 
homeostasis. (A) Splenomegaly and representative sections of (B) heart (20x 
magnification) and (C) epicarditis (400x magnification) in IP KO mice at the age of 36 
weeks. (D) Number of cells in the spleens of IP KO and WT mice. (E) Splenic CD3+, (F-
G) CD3+ CD4+, (H-I) CD4+ CD25+ Foxp3+ Tregs in IP KO and WT mice. (J) Foxp3 MFI 
and (H) CD25 MFI of splenic CD4+ CD25+ Foxp3+ Tregs IP KO and WT mice. Data 
plotted as mean + SEM. n = 2 mice per group (A-C). n = 15 mice per group combined 
from 3 independent experiments (D-J). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired 
T-test (D-J).  
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Figure 4.2. IP-deficient Tregs are less suppressive in vitro. Suppression assays 
were performed using purified CD4+CD25– Teff and CD4+CD25+ Tregs. (A) Comparison 
of inhibition at varying ratios of Tregs to Teff. Percent (B) suppression and (C) 
proliferation of Teff from WT mice in co-culture with Tregs from IP KO or WT mice. IL-10 
(D) and IL-5 (E) production in cultured supernatants of Tregs stimulated with anti-CD3 
and anti-CD28. Data plotted as mean + SEM. n = 3 representative of 2 independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA (A-C) or unpaired 
T-test (D-E).  
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cytokine IL-5 in the supernatants of stimulated Treg cultures from IP KO mice compared 
to supernatants of stimulated Treg cultures from WT mice (Figure 4.2D & E). 
Stimulated Tregs from IP KO mice also produced less IFN-γ and IL-17 compared to 
stimulated Tregs from WT mice (Figure 4.3A & B). We did not find statistically 
significant differences in production of TGF-β, IL-2, IL-4, and IL-13 (not detected) 
between stimulated Tregs from IP KO and WT mice in vitro (Figure 4.3C-E). Increased 
Th2 cytokine production was also observed in supernatants of stimulated naïve CD4+ T 
cells from IP KO mice compared to supernatants of stimulated naïve CD4+ T cells from 
WT mice.263 Thus, Th2 responses are broadly and selectively dysregulated in mice 
lacking PGI2 signaling. 
To determine whether Teff from IP KO mice are also resistant to Treg-mediated 
suppression, we incubated both WT and IP KO Teff with WT Tregs. The ability of WT 
Tregs to suppress IP KO Teff proliferation was reduced compared with their inhibition of 
WT Teff (Figure 4.4). Together, these data suggest that PGI2 enhances both Treg 
function and Teff responsiveness to Treg-mediated suppression. 
 
IP deletion inhibits iTreg differentiation 
As iTregs act in concert with other Treg subpopulations to maintain peripheral 
tolerance, we further hypothesized that endogenous PGI2 signaling may modulate in 
vitro iTreg differentiation in addition to Treg stability and function. To test this, we 
isolated naïve CD4+ CD62L+ T cells from Foxp3-GFP x IP KO and Foxp3-GFP mice 
using commercially available magnetic sorting kits (Miltenyi). As optimal iTreg 
differentiation from naïve CD4+ T cells  
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Figure 4.3. Stimulated Tregs from IP KO mice produce less IFN-γ and IL-17 and 
similar amounts of TGF-β, IL-2, and IL-4 compared to Tregs from WT mice. IFN-γ 
(A) IL-17 (B), TGF-β (C), IL-2 (D), and IL-4 (E) production in cultured supernatants of 
Tregs stimulated with anti-CD3 and anti-CD28. Data plotted as mean + SEM. n = 3 
representative of 2 independent experiments.  
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Figure 4.4. IP-deficient Teff are resistant to Treg-mediated suppression. 
Suppression assays were performed using purified CD4+CD25– Teff and CD4+CD25+ 
nTregs. (A) Comparison of inhibition at varying ratios of nTregs to Teff. Percent (B) 
proliferation and (C) suppression of Teff from IP KO or WT mice in co-culture with 
nTregs from WT mice. Data plotted as mean + SEM. n = 3 representative of 2 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA.  
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results from weak anti-CD28 costimulation,264 naïve CD4+ T cells were stimulated with 
anti-CD3 and cultured in the presence of IL-2 (0.25 µg/mL) and TGF-β (1 µg/mL) for 6 
days. IP deletion significantly increased the proliferative competence of naïve CD4+ T 
cells from IP KO mice compared to naïve CD4+ T cells from WT mice (Figure 4.5A & 
B). However, IP deletion significantly decreased the percentage of Foxp3-expressing 
iTregs that differentiated from naïve CD4+ T cells compared to WT mice (Figure 4.5C & 
D). Thus, our data indicate that PGI2 is a novel cofactor in TGF-β-mediated iTreg 
generation. 
 
Tregs attenuate Th2 responses in an OVA-induced airway inflammation model 
As PGI2 has been implicated in Th2-mediated immune diseases, we developed 
an antigen-induced airway inflammation model of asthma to assess the in vivo 
suppressive function of nTregs (Figure 4.6). Teff and Tregs were adoptively transferred 
into Rag2-/- mice that had been challenged with OVA protein intranasally (i.n.) or saline 
one day before cell transfer to promote cell migration to the airways.42 Following cell 
transfer, mice were challenged with OVA (i.n.) or saline for three consecutive days and 
sacrificed one day after the last OVA challenge to measure lung homogenate levels of 
IL-13, which mediates airway mucus production. Reconstitution with Teff resulted in 
appreciable lung homogenate levels IL-13. Mice that received Teff without OVA 
challenge or mice challenged with OVA without Teff transfer had lung homogenate 
levels of IL-5 and IL-13 that were <50 pg/ml (data not shown). Transfer of WT Tregs 
inhibited the lung levels of IL-13 (Figure 4.7). 
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Figure 4.5. IP deletion inhibits iTreg development from naïve CD4+ T cells. Naïve 
CD4+ T cells from IP KO and WT mice were activated with anti-CD3 and differentiated 
into iTregs by adding IL-2 and TGF-β. (A) Representative CFSE dilution measured by 
flow cytometry in activated naïve CD4+ T cells. (B) Percent proliferation of activated 
naïve CD4+ T cells. (C) Representative Foxp3 expression measured by flow cytometry 
in differentiated iTreg. (D) Percent of CD4+ T cells that are CD25+ Foxp3+. Data plotted 
as mean + SEM. n = 3 representative of 3 independent experiments. *p < 0.05, **p < 
0.01 by one-way ANOVA. 
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Figure 4.6. Protocol for in vivo model of OVA-induced airway inflammation. Rag2-
/- mice were challenged with OVA protein (50 μg) i.n. on day -1. On day 0, Teff from 
DO11.10 mice (2.5 x 106) and nTregs from DO11.10 mice (0, 0.5, or 2 x 106) were 
transferred into the recipient mice. Mice were subsequently challenged with 50 μg OVA 
for 3 consecutive days. Mice were sacrificed on day 4, one day after the last airway 
challenge. Cytokine and chemokine levels in the BAL fluid and lung homogenate were 
determined by ELISA. 
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Figure 4.7: Tregs attenuate Th2 responses in an OVA-induced airway 
inflammation model. Rag2-/- mice received Teff and Tregs from DO11.10 mice in a 
model of OVA-induced airway inflammation. ELISA for IL-13 in whole lung homogenate. 
Data plotted as mean + SEM. n = 3 mice per group.   
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Pglyrp1 and Ccdc61 are decreased in IP-deficient Tregs 
To further investigate the molecular mechanisms by which PGI2 regulates the 
function of Tregs, we isolated Tregs from IP KO and WT mice and comparatively 
analyzed the transcriptomes of these cells by next-generation sequencing-based RNA 
sequencing (RNA-seq). IP-deficient and IP-sufficient Tregs exhibited similar expression 
of many molecules with a presumed role in the suppressive properties of Tregs. We 
confirmed that result on the protein level by flow cytometry for the immunomodulatory 
receptor CTLA-4, the ATP ectonucleotidase CD39, and the IL-2 receptor complex (data 
not shown). However, mRNA expression of Pglyrp1 and Ccdc61 was significantly 
decreased in IP-deficient Tregs compared to WT nTregs (Figure 4.8A). Subsequent 
independent confirmation by qPCR showed statistically significant 5-fold decreases in 
Pglyrp1 and Ccdc61 expression in IP-deficient Tregs compared to WT Tregs (Figure 
4.8B & C). 
 
Discussion 
Allergic diseases affect up to 30% of the population worldwide, with asthma 
being one of the most common chronic diseases in which affected individuals may 
suffer considerable mortality.1,2 Although corticosteroids are effective at managing most 
disease, 10% of patients do not respond to the treatment, and they are associated with 
severe long-term side effects. Whereas healthy individuals have more Tregs than Th2 
effector cells, allergic patients have a defect in either the number of regulatory cells, 
their suppressive activity, or both.265,266 Various approaches to redress the balance 
between regulatory and effector cells, such as allergic-specific immunotherapy and  
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Figure 4.8. Pglyrp1 and Ccdc61 are decreased in IP-deficient Tregs. RNA-seq was 
performed on RNA isolated from splenic nTregs of WT and IP KO mice. (A) Volcano 
plot of genes downregulated in IP KO nTregs relative to their expression in IP-sufficient 
Treg cells. (B) Plygrp1 and (C) Ccdc61 mRNA expression by qPCR. Each sample is 
normalized to GAPDH and relative expression is compared to that of nTregs from WT 
mice. Data plotted as mean + SEM. n= 5-6 mice per group representative of 2 
independent experiments. *p < 0.05 by unpaired T-test (B). 
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biologics targeting cytokines or immunoglobulin E (IgE), have been tested, but each has 
limitations. Administration of Tregs to restore immune tolerance has been explored as a 
potential therapeutic approach to asthma as well as transplantation and autoimmune 
diseases. 248–250 The present study describes PGI2 as a new modulator of Treg function. 
The effect of PGI2 on Treg stability has not been described. Our group has 
previously shown that IP KO mice have greater numbers of Tregs during aeroallergen-
induced immune tolerance.267 Here we similarly report that IP KO mice had increased 
numbers of Tregs compared to WT mice under homeostatic conditions. However, IP-
deficient Tregs demonstrated decreased Foxp3 protein expression on a per Treg basis. 
This finding suggests that the increased number of Treg cells in IP KO mice is an effort 
to maintain inflammatory homeostasis in these mice compared with WT mice. Currently, 
there are insufficient animals to make a valid statistical analysis to determine whether 
the findings of autoimmune manifestations in the aged IP KO mice are due to chance. 
However, we will have the opportunity to determine if there is a significant difference in 
autoimmune manifestations in aged IP KO versus WT mice in the future. The IP-
deficient Treg population might show enrichment for cells with unstable Foxp3 
expression. A population of CD25- Foxp3+ Tregs with lower Foxp3 expression was 
recently described.268 Future studies will determine whether PGI2 signaling leads to 
enrichment of this less stable Treg population. IP-deficient Tregs were less suppressive 
in in vitro suppression assays. Moreover, IP-deficient Teff were resistant to Treg-
mediated suppression in vitro. The Th2 response mediates allergic airway inflammation 
and is correlated with disease severity. Some studies suggest that Teff resistance to 
Treg-mediated suppression contributes to asthma pathology in addition to Treg 
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dysfunction.269 The stability of Tregs during inflammation has been called into question 
with multiple reports demonstrating evidence of Treg plasticity, whereby 
immunoregulatory Tregs revert into pathogenic Teff during inflammation.270–274 We 
found evidence of altered stability of IP-deficient Tregs in that ex vivo stimulation of 
Tregs from IP KO mice induced delayed IL-10 production and greater IL-5 production 
compared to Tregs from WT mice. These results are consistent the finding that iloprost-
treated dendritic cell (DC)s induced the generation of IL-10-producing Tregs.275 PGI2 
may enable the reprogramming of Tregs into effector Th2 cells. Further, Treg 
dysregulation may contribute to the enhanced Th2 immune response and airway 
inflammation observed in IP KO mice. 
An emerging concept of Treg modulation is the acquisition of other Th-specific 
transcription factors, which renders Tregs capable of specifically controlling the 
respective Th-mediated immune responses. For example, Treg-specific suppression of 
Th1 , Th2, and Th17 cells was demonstrated through specific transcription factors 
expressed in Tregs including T-bet, IRF4, and STAT3.51,276,277 Of relevance to this 
study, the initiation of Th2 cell-driven immune responses was dependent on expression 
of the transcription factor IRF4 which endowed Tregs with the ability to suppress Th2 
responses in vivo.51 Recent studies demonstrated that Bcl-6 and Csnk2b also promote 
Th2 responses and modulate Treg function.50,278 IP-deficient Tregs did not show altered 
expression of IRF4, Bcl-6, or Csnk2b (data not shown). Recent studies have identified a 
number of potential mechanisms involved in Treg suppression that may be useful for 
enhancement of suppression and/ or Treg numbers including CD39 signaling and 
CTLA-4. However, data from the current study demonstrate that expression of these 
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molecules were unaltered between Tregs from IP KO versus WT mice. Thus, the 
present study suggests that Tregs use unique PGI2-controlled mechanisms to protect 
against inflammation. 
 Pglyrp1 and Ccdc61 expression was decreased in IP deficient versus IP-
sufficient Tregs. While less is known about Ccdc61, Pglyrp1 - originally identified for its 
role in antibacterial innate immunity-279 was identified as having a role in asthma in a 
genome-wide profiling of the lung transcriptome of mice with human dust mite (HDM)-
induced experimental asthma.280 Pglyrp1 has demonstrated pro-inflammatory effects in 
three mouse models of inflammatory skin diseases, including atopic dermatitis, contact 
dermatitis, and psoriasis.281,282 Moreover, Treg activity and recruitment to the skin was 
decreased in mice that lacked Pglyrp1 in a mouse model of chemically induced, 
psoriasis-like inflammation.281 A subsequent study by the same group found higher 
numbers of Tregs in the lungs of mice that lacked Plygrp1 in a mouse model of HDM-
induced experimental asthma.283 The authors posit that their disparate findings 
regarding the effect of Pglyrp1 on Tregs could be explained by an underlying role for 
Pglyrp1 in inhibiting plasmacytoid (p)DCs that activate Tregs in their second study. In 
addition to possibly Pglyrp1, a transcriptional module downstream of PGI2 signaling is 
likely modified to facilitate efficient Teff suppression by Tregs. Treg populations may be 
heterogeneous in this regard, if signaling-dependent post-translational modifications of 
PGI2 signaling or recruitment of other nuclear factors are needed for Treg-mediated 
suppression. We propose that PGI2 signaling might alter certain components of 
transcriptional machinery promoting Treg stability and function to efficiently control the 
present immune response. It is likely that changes in expression of a combination of 
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genes, but not a single gene, account for the impaired suppressor capacity of IP-
deficient Tregs. Additionally, PGI2 may coordinate with several stabilizing factors to 
induce Foxp3 protein expression in CD4+ T cells given the diverse proinflammatory 
stimuli Tregs may encounter in their lifespan. Identification of these stabilizing factors 
and further characterization of the molecular mechanism underlying the Foxp3-
stabilizing effect of PGI2 will help provide a full molecular picture on the physiological 
regulation of Tregs, as well as establish the basis for the application of Tregs in 
immunotherapy. 
 The Food and Drug Administration (FDA) has approved PGI2 for treatment of 
primary pulmonary hypertension. PGI2 has also been used safely and effectively in 
patients with other causes of pulmonary hypertension, including the inflammatory 
conditions scleroderma and systemic lupus erythematosus.151 The attenuation of Treg-
mediated suppression by drugs is a promising therapeutic strategy that has mediated 
the attenuation of some conditions such as organ rejection and Crohn’s disease.284,285 
However, whether PGI2 exerts anti-inflammatory effects in vivo in part by promoting 
Treg function and thereby breaching immunological unresponsiveness to allergens 
remains to be elucidated. Our results identify a new function for PGI2 as an important 
link between anti-inflammation and the local Treg response. The ability of PGI2 to 
promote regulatory networks in response to inflammation may represent a more general 
mechanism by which PGI2 and other anti-inflammatory prostaglandins such as PGE2 
limit immune-mediated damage to self at barrier tissues.286,287 
Together, these data suggest that PGI2 creates a protolerogenic environment 
that is potent enough to promote Treg and suppress Teff responses. PGI2 has appeal 
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for a broad range of inflammatory diseases that are driven by an imbalance between 
pro- and anti-inflammatory T cell responses and have reached alarming prevalence in 
industrialized nations.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary of findings 
 Patients with asthma have innate immune defects with pathogens, which may 
partially explain why these individuals are at increased risk for invasive bacterial 
infections and bacterial pneumonia. γδ T cells reside at the interface of epithelial-
environmental interfaces such as the respiratory and gastrointestinal tracts, and are a 
critical first line of defense against bacterial and fungal pathogens. A subset of γδ T 
cells are the γδ17 cells which produce large quantities of IL-17, a cytokine crucial to the 
anti-bacterial and anti-fungal function of these cells. IL-4 is produced at high levels in 
the airway of asthma patients. I found that γδ T cell expression of the type I IL-4R is 
functional, as IL-4 induces STAT6 phosphorylation in γδ T cells. IL-4 inhibits γδ17 cell 
production of IL-17. IL-4 also decreases Sgk1 expression, which may lead to 
destabilized IL-23R expression on γδ17 cells. Endogenous IL-4 reduces lung γδ17 cell 
numbers during acute KP infection. IL-4 inhibition of γδ17 cells provides a possible 
explanation for why asthmatic patients are at greater risk for invasive bacterial disease 
(Figure 5.1 & Chapter I). 
 GLP-1R agonists are a well-accepted and safe treatment for T2D. Recent 
evidence suggests that GLP-1R signaling also has anti-inflammatory effects. Severe 
RSV-associated illness is in part caused by type 2-associated immunopathology. GLP-
1R agonist treatment attenuated immunopathology during RSV infection. The GLP-1R 
agonist decreased total lung IL-13 and IL-33 levels, with concurrent decreases in IL-13+  
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 Figure 5.1. STAT6 attenuates γδ 17 cells.  
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group 2 innate lymphoid cell (ILC2), CD4+ Th2 cells, and basophils as well as IL-33+ 
epithelial cells. GLP-1R agonist treatment prevented airway inflammation, and did not 
impact viral load, anti-viral interferon and antibody production during secondary RSV 
infection. Relative to the respective mock-infected groups, RSV-infected GLP-1R 
agonist-treated mice did not have increased weight loss compared to vehicle-treated 
mice. A phenome-wide association study (PheWAS) identified a link between GLP-1R 
signaling and acute bronchitis and bronchiolitis in humans. GLP-1R agonists are the 
first known FDA-approved agents to inhibit IL-33 and may represent a novel treatment 
strategy for RSV bronchiolitis (Figure 5.2 & Chapter II). 
 Tregs suppress immune responses and maintain tolerance by inhibiting T cell 
activation. There is extensive interest in the application of Tregs in allergic diseases. 
PGI2 signaling through the IP receptor inhibits inflammation and promotes tolerance 
during allergic airway inflammation. I found that PGI2 protects against autoimmunity and 
promotes nTreg stability and suppressive function as well as iTreg differentiation. PGI2 
simultaneously promotes Teff proliferation and susceptibility to nTreg-mediated 
suppression. Thus, PGI2 may represent a novel treatment strategy for diseases that 
result from Treg dysregulation (Figure 5.3 & Chapter III). 
 
Future directions 
Targeting single components of the immune system versus the network as a whole 
There is considerable interest in targeting multiple components of the immune 
system to attenuate airway inflammation. Corticosteroids, the most widely prescribed 
therapeutic for allergic asthma, function by broadly suppressing immune responses. 
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Figure 5.2. GLP-1 attenuates RSV-induced immunopathology.  
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Figure 5.3. PGI2 orchestrates Treg and Teff responses.  
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However, in 5-10% of patients, the disease is refractory to corticosteroid treatment and 
often leads to hospital admissions caused by respiratory viral and/ or bacterial 
infections. Corticosteroid use for RSV disease is similarly limited, with studies 
examining the effect of corticosteroid, bronchodilator, and anti-viral ribavirin therapy 
routinely showing no improvement compared to placebo for RSV bronchiolitis. 
Palivizumab, the only FDA-approved preventative therapy, is currently only 
recommended for infants in the first year of life with underlying conditions. The 
development of novel preventative and therapeutic strategies is imperative given the 
prevalence of the poorly-controlled asthma patient population and the lack of 
interventions that improve outcomes for RSV bronchiolitis once infection has occurred. 
 This need formed the basis of my investigations in which I explored whether γδ17 
cell attenuation could provide an explanation for why asthmatic patients have 
significantly greater risk for invasive bacterial disease than nonasthmatic subjects 
(Chapter I), whether type 2 immune response inhibition could result in decreased 
immunopathology during RSV infection (Chapter II), and whether an anti-inflammatory 
agent could enhance the function of Tregs, an important cellular mediator of 
inflammation (Chapter III). 
 
Heterologous immunity as a barrier to regulating airway inflammation 
 Multifaceted immune responses during inflammation present a significant 
challenge to attenuating pathogenic inflammatory responses while preserving protective 
host immune mediators during airway disease. In vivo small animal models of disease 
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allow the study of separate components of the immune response when examining the 
downstream consequences of potential therapeutic agents in preclinical studies. 
In Chapter I, I found that endogenous IL-4 reduces lung γδ17 cell numbers 
during acute KP infection. Whether STAT6 signaling attenuates γδ17 cells and 
subsequent protective neutrophilic infiltration and bacterial burden in the context of 
allergic airway inflammation remains to be determined. Additional studies using mouse 
models of allergic airway inflammation with subsequent bacterial infection would shed 
further light on the impact of the Th2 cytokine-rich milieu in the asthmatic lung on the 
subsequent development of bacterial pneumonia. In Chapter II, I found that GLP-1 
signaling has no effect on the production of the Th1 cytokine IFN-γ when administered 
therapeutically during RSV infection. However, a study by another group reported that 
GLP-1R agonist administration inhibited invariant (i)NKT cells secretion of IFN-γ in vitro. 
The effect of GLP-1 signaling on cellular IFN-γ production likely depends on the unique 
combination of secondary signaling pathway(s) activated by GLP-1 in distinct cell types. 
Future studies elucidating the signaling pathways utilized by GLP-1 in different immune 
cells will enhance our understanding of GLP-1 immunobiology. In Chapter III, I found 
that PGI2 signaling promotes nTreg suppressive function. Although PGI2 exhibits anti-
inflammatory effects in most disease models studied to date, PGI2 has been described 
to have a pro-inflammatory role in the context of rheumatoid arthritis. Thus, PGI2’s 
overall effect on inflammation is likely governed by the timing, location, and context of 
immune responses. Additional studies are currently underway in our group to 
investigate the role of PGI2 signaling on nTregs in a Th2-driven mouse model of allergic 
airway inflammation as well as in Th1-driven mouse models of colitis and lupus. These 
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studies will reveal whether PGI2 signaling consistently enhances Treg function in Th1 
versus Th2, inflammatory versus autoimmune, and localized versus systemic disease 
conditions. 
 
Precision medicine for airway inflammation 
 The rapid increase in scientific and bioinformatics tools that can be used to 
generate and search vast amounts of experimental, clinical, genetic, phenotypic, 
environmental, and demographic data to yield new knowledge about various disorders 
has yielded a new era of precision medicine. The driving vision behind the precision 
medicine initiative aims to develop an approach for disease treatment and prevention 
that takes into account individual variability for each person. 
In the field of asthma, recent studies suggest that identifying distinct subsets of 
patients leads to more favorable responses to biologics that impair the functioning of the 
unique pathways involved in airway pathology. 288 For example, patients whose asthma 
is associated with increased levels of biomarkers of a Th2 phenotype have 
demonstrably benefitted more from therapy targeting elements of the Th2 response 
compared to patients with low levels of Th2 biomarkers.131,289,290 My findings in Chapter 
I suggest that drugs targeting the IL-4 pathway could have detrimental effects on anti-
bacterial host immunity in asthma patients. Conversely, my findings in Chapter III 
suggest that PGI2 creates a protolerogenic environment that is potent enough to 
promote nTreg suppressive function and suppress Teff responsiveness to Treg-
mediated suppression. These findings will contribute to the growing body of data our 
 125 
scientific community will use to construct our initial working models of precision 
medicine for asthma treatment.  
In the field of RSV disease, delineating the roles of viral and host factors in RSV 
immunopathology will better inform therapeutic strategies. Our group has been the first 
to sequence and identify RSV strains significantly associated with significantly 
increased risk of recurrent wheezing outcomes in infants as well as differential immune 
responses in mice. In Chapter II, we demonstrated that GLP-1R signaling attenuated 
RSV-induced immunopathology using a strain of RSV that was isolated from a 
hospitalized infant with severe lower respiratory tract infection and bronchiolitis from 
these studies. This strain contained a previously described mutation of 2 tandem stop 
codons for the RSV attachment glycoprotein (G) gene (2stop-A4G), which was 
associated with enhanced bronchiolitis severity in infants. The continuation of these 
studies will reveal whether RSV strains containing the 2stop-A4G mutation also 
associate with the development of RSV immunopathology and later childhood asthma. 
To this end, our group has recreated several recombinant viruses with the G and F 
proteins of clinical isolates containing 2stop-A4G or WT sequences using a reverse 
genetics approach. Our hypotheses for these future studies are that infection with RSV 
strains that contain the 2stop-A4G mutation enhance innate and adaptive Th2 immune 
responses, and augment subsequent allergic airway inflammation while exacerbating 
existing allergen- induced airway inflammation. Additional future work should be done to 
examine whether our finding that GLP-1R signaling attenuated RSV-induced 
immunopathology is also observed using additional pathogenic and/ or 2stop-A4G 
clinical strains of RSV. 
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RSV predominantly infects infants, with age as the principal risk factor for severe 
disease. Differences in the immune response to RSV in the very young are postulated 
to be critical in determining the clinical outcome of RSV infections. Thus, the effect of 
host age on the development of immunopathology and severe disease following RSV 
infection remains a critical question in the field. The neonatal immune response to RSV 
infection has been characterized by observed patterns of skewing towards Th2 and 
Th17 polarization and away from protective Th1 responses. However, no studies to date 
have compared differential responses of primary bronchial epithelial cells, the host cell 
for RSV, between infants and older populations during infection. Differentiating primary 
epithelial cells from humans in air-liquid interface (ALI) cultures represents a valuable 
tool for recapitulating the in vivo human bronchial epithelium. Given our group’s unique 
access to difficult-to-attain specimens, a future study should analyze the differentially 
expressed transcriptome of primary infant versus toddler bronchial epithelial cells in ALI 
cultures infected with pathogenic RSV strains collected from infants with severe 
bronchiolitis. Such a study would provide clinically-relevant insight into which factors 
critical to initiating the protective immune response to RSV infection may be lacking in 
the neonatal bronchial epithelium. 
The PheWAS algorithm represents a recently developed tool that allows for the 
linkage of subject-level deidentified genotyping information with electronic medical 
record-derived clinical phenotypes. In Chapter II, a PheWAS identified a link between 
GLP-1R signaling and acute bronchitis and bronchiolitis, corroborating our findings 
demonstrating the significance of GLP-1R signaling during RSV infection and expanding 
the relevance of these findings to humans. Additional studies are currently underway in 
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our group to examine whether genetic variants that affect GLP-1 and PGI2 signaling 
also associate with allergic disease phenotypes. 
 
Towards reliably controlling immune responses during airway inflammation 
 Although controlling aberrant immune responses during various states of airway 
inflammation has been demonstrably achieved in small animal models of disease, a 
significant poorly-controlled asthma patient population and a lack of interventions that 
improve outcomes for RSV bronchiolitis once infection has occurred still remain. 
 In Chapter I, I found that IL-4 also attenuates γδ17 production of IL-17 in a 
STAT6-independent manner. Further studies elucidating the molecular determinants of 
this finding could help circumvent the potential detrimental effects of anti-IL-4 therapies 
on anti-bacterial host immunity in asthma patients. In Chapter II, I found that treatment 
with a GLP-1R agonist attenuated IL-33 and immunopathology during RSV infection. 
GLP-1R agonists are the first known FDA-approved agents to inhibit IL-33, an important 
therapeutic target in inhibiting airway disease given its central role in mediating both 
innate and adaptive immunity-regulated lung inflammation. Thus, our group is currently 
working on elucidating the mechanisms by which GLP-1 signaling inhibits IL-33 
production in human bronchial epithelial cells. Aerosolized and pathway-specific GLP-
1R agonists are needed for more localized and potent as well as less off-target effects 
for treatment of airway inflammation. Dr. Niswender, our collaborator and GLP-1 expert, 
is actively working with Dr. Craig Lindsley to develop such new agents for clinical use. 
There are many barriers currently precluding the effective use of clinical Treg-
based therapies. Such barriers include Treg plasticity, whereby therapeutic, 
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immunoregulatory cells revert into pathogenic effectors of the immune system; 
concomitant use of immunosuppressants that interfere with Tregs; and obtaining 
sufficient numbers of Tregs from a single donor. In Chapter III, we found that PGI2 
promotes nTreg function and may represent a new treatment strategy for Treg-mediated 
diseases. Future studies further exploring this finding would greatly benefit from the 
generation of a mouse model in which IP deletion is inducible and specifically limited to 
Foxp3-expressing Tregs. Such a model would allow greater resolution in studying the 
effect of PGI2 on Tregs, enabling the collection of data looking into the role of PGI2 on 
Tregs during development and in tissue-specific regions. The generation of a mouse 
model in which IP deletion is combined with fate-mapping of Foxp3-expressing Tregs 
would also allow further study of the effect of PGI2 on Treg plasticity and the generation 
of ex-Tregs. The findings in this work contribute to our understanding of how to enhance 
Treg function, alongside current efforts to delineate more active Treg subsets and more 
potent antigen-specific Tregs. Future efforts in Treg research should also be directed 
towards overcoming the clinical barriers to the use of Treg-based therapies. 
As discussed in Chapter I, recent therapeutic strategies for treating allergic 
asthma have targeted downstream IgE and Th2 cytokines such as IL-4, IL-5, IL-13, and 
IL-17. The most recent emerging therapies for attenuating type 2-related airway 
inflammation are targeting upstream mediators such as TSLP, IL-33, and GATA3. 
Interestingly, these upstream-acting therapies have shown efficacy in a broader range 
of diseases- including atopic dermatitis and colitis- in which Th2 responses play a role.  
There is much to learn from other fields that have successfully tailored immune 
responses for more effective disease resolution. For example, chimeric antigen receptor 
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(CAR) T cells specifically target cancer cells and significantly increased survival rates in 
some forms of cancer. One could imagine extending this approach to generate chimeric 
antigen receptor Tregs or inhibitory IgG-secreting plasma cells specific for certain 
allergens. Immune checkpoint inhibitors re-activate cytotoxic T cells and also 
demonstrated efficacy in reducing tumor size. Activation and ligation of the cell surface 
receptor programmed cell death protein 1 (PD-1) results in apoptosis. PD-1 was also 
recently found on iNKT cells and ILC2. Blocking PD-1 with an anti-PD-1 antibody 
reduced IL-13-producing ILC2 during influenza infection as well as IL-5-producing ILC2 
and lung inflammation during airway challenge with the protease allergen papain. Anti-
PD-1 antibody also prevented CD8+ T cell impairment and reduced viral titers during 
acute viral lower respiratory infection with human metapneumovirus, suggesting that 
immune checkpoint inhibition could dually attenuate type 2 immunopathology while 
enhancing anti-viral host immune responses. 
Numerous pathogenic versus protective bacterial species have been identified as 
modulators of airway inflammation. For example, dietary Lactobacillus johnsonii 
supplementation protected against both airway allergen challenge and RSV infection. I 
contrast, nasal Streptococcus and Haemophilus colonization have been linked to 
increased RSV disease severity. Similar to fecal transplantation for the treatment of 
Clostridium difficile infection, the future of treatment for airway inflammation could very 
well entail cocktails enriched in protective bacterial species engineered to outcompete 
pathogenic microbes. Future characterization of the human microvirome will 
undoubtedly uncover new players in airway inflammation. 
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Engineered microbes have additionally been used as delivery vehicles for 
therapeutic agents such as cytokines, antigens, antibodies, or genetic materials. 
Inoculation with innocuous lung commensals engineered to release immunoregulatory 
cytokines or anti-inflammatory antibodies could represent a valuable therapeutic 
strategy for combating airway disease. Many groups are also designing synthetic 
materials to optimize the spatial and temporal delivery of drugs. Specifically, an array of 
nanoparticles, engineered cell-nanoparticle combinations, and cytokine-releasing 
microspheres are in development to target the correct tissue site, control entry into the 
cell, and moderate the kinetics of drug signal delivery. Similarly, engineered exosomes 
are emerging as promising drug delivery vehicles given their cell membrane 
composition which include key adhesive proteins. 
Identifying new therapeutic targets, developing new therapies and modes of drug 
delivery, determining optimal combinations of new drugs with previous-line therapies, 
and continually fine-tuning the application of therapeutic regimens in line with our 
understanding of disease endotypes and host pharmacogenomics will all be critical 
towards realizing the goal of controlling immune responses during airway inflammation. 
 
Conclusions 
 The striking rise in the prevalence of allergic diseases has been accompanied by 
the rapid growth of technology and resources devoted to developing treatments for 
these disorders. Effectively controlling immune responses during various states of 
airway inflammation will require targeting multiple components of the immune system 
with great precision. The work presented here reveal new insights regarding the 
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regulation of specific immune modulators of allergic airway inflammation as well as 
acute pulmonary bacterial and viral infection. As we learn to control the various 
mediators of airway inflammation, our greatest challenge moving forward is translating 
these findings into the clinic. In the long run, our ability to integrate and translate our 
findings into meaningful, clinical therapies will dictate the next phase of progress in the 
field of asthma and immunology, hopefully making infectious asthma exacerbations, 
poorly-controlled asthma, and RSV-related morbidity and mortality things of the past. 
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